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ABSTRACT  Introduction: HIV exposed but uninfected infants have been shown to have a higher morbidity and mortality than unexposed infants.  There is almost no literature comparing the short-term outcomes of HIV exposed versus unexposed VLBW neonates who are born prematurely.  Methods: A retrospective review of all VLBW neonates who were admitted at Groote Schuur Hospital nursery from 2012-2014. Data were obtained from the Vermont Oxford Database and the Prevention of Mother to Child register. Results: A total of 1593 VLBW neonates were admitted during the 3 years of which it was possible to obtain maternal HIV status in 1579 babies. Of these 1579 babies, 316 (20%)were HIV exposed. Eleven of the 230 (4.8%)infant HIV tests were positive. There was no difference in mortality, birth weight, gestational age, length of stay, sepsis and delivery room outcomes for the HIV-exposed (HIVE), maternal ARV-exposed (mARVE) and HIV-positive neonates. Differences between HIV exposed and HIV unexposed neonates were noted in an increased risk of NEC [OR 1.83 (1.2-2.8)] and an increased need for ventilation [OR 1.35 (1.01-1.8)]. Maternal antiretroviral exposed neonates developed less NEC compared with maternal antiretroviral under-exposed neonates with a birth weight under 1000grams appearing to contribute in the development and outcome of NEC. Differences in HIV-positive neonates included more chronic lung disease [OR 5.49 (1.31-23)] and more necrotising enterocolitis [OR 4.12 (1.02-17.18)]. Conclusion: This study is the first to compare the short-term outcomes of HIV exposed and HIV unexposed very low birth weight infants and consider maternal ARV exposure. It demonstrated no difference in birth weight, gestational age, mortality or sepsis. Necrotising enterocolitis is increased in the HIV exposed neonates especially if they are under-exposed to maternal antiretrovirals. Adequate maternal antiretrovirals may have a protective effect on incidence of necrotising enterocolitis and respiratory outcomes.   
 5 
ACKNOWLEDGEMENTS  
 It is virutally impossible to produce anything of much significance entirely on your own.  Thank-you:   To my supervisor who was incredibally patient, surprisingly gentle when he was disappointed and always managed to get me to come back with an even better version after I was convinced it had looked great. To Ms Gabeba Abass, who sourced all the folders and saved me the trouble and time of having to negotiate the archives.  To my family and friends, who made cups of tea and coffee, tried to explain statistics to me, let me try and explain the complexities of some of the concepts, cheered from the sidelines and dragged me over the finish line.  Lastly to the babies, who create the opportunity to learn and understand so that we know better for next time.  This is for all of you.   
 6 
LIST OF TABLES 
 
Table 1.1: Summary of studies on mortality .............................................................................................................. 19 
Table 1.2: Summary of studies on all-cause morbidity .......................................................................................... 20 
Table 1.3: Summary of studies on neonatal jaundice and respiratory distress syndrome ...................... 21 
Table 1.4: Summary of studies on sepsis ..................................................................................................................... 22 
Table 1.5: Summary of studies on necrotising enterocolitis ................................................................................ 23  
Table 2.1: PMTCT regimens during time of study (2012 - 2014) ...................................................................... 31  
Table 3.1.1: Ethnicity of cohort by HIV status ........................................................................................................... 33 
Table 3.1.2: Maternal characteristics for HIVE and HIVU neonates. ............................................................... 34 
Table 3.1.3: Neonatal outcomes of HIVE and HIVU infants ................................................................................. 37 
Table 3.1.4: Sub-group analysis of HIVE and HIVU neonates who required ventilation .......................... 38 
Table 3.1.5: Sub-group analysis of HIVE and HIVU neonates who developed NEC. ................................... 39 
Table 3.1.6: Feeding at discharge for HIVE and HIVU neonates. ....................................................................... 40 
Table 3.2.1: Maternal characteristics of mARVE and mARVU neonates. ....................................................... 42 
Table 3.2.2: Neonatal outcomes for mARVE and mARVU infants ..................................................................... 45 
Table 3.2.3: Sub-group analysis of mARVE and mARVU neonates who developed NEC .......................... 46 
Table 3.3.1: Maternal Characteristics of HIV-PCR positive and HIV-PCR negative neonates. ............... 49 
Table 3.3.2: Neonatal outcomes of HIV-PCR  positive and HIV-PCR  negative neonates. ........................ 52 
Table 3.3.3: Subgroup analysis of HIV-PCR  positive and HIV-PCR  negative neonates who required 
non-invasive ventilation. ................................................................................................................................................... 53 
  
 7 
LIST OF FIGURES 
 
Figure 1.1: Flow diagram of article selection process……………………………………………………………………14  
Figure 3.1.1: Distribution of the cohort based on HIV-exposure status .......................................................... 33 
Figure 3.1.2: Box plot distribution for birth weight of HIVE vs. HIVU neonates. ......................................... 34 
Figure 3.1.3: Box plot distribution for gestational age of HIVE and HIVU neonates. ................................ 35 
Figure 3.1.4: Box plot distribution for length-of-stay for  
HIVE and HIVU neonates ................................................................................................................................................... 35 
Figure 3.1.5: Box plot distribution of birth weights for HIVE vs. HIVU neonates who developed NEC
 ..................................................................................................................................................................................................... 39  
Figure 3.2.1: Distribution of maternal antiretroviral (ARV) exposure among the HIV-exposed cohort
 ..................................................................................................................................................................................................... 41 
Figure 3.2.2: Box plot distribution of gestational ages for mARVE and mARVU neonates ..................... 43 
Figure 3.2.3: Box plot distribution of birth weight for mARVE and mARVU neonates. ............................ 43 
Figure 3.2.4: Box plot distribution of length-of-stay for mARVE  and mARVU neonates. ........................ 44 
Figure 3.2.5: Box plot distribution of birth weight of mARVE and mARVU neonates who developed 
NEC ............................................................................................................................................................................................. 46  
Figure 3.3.1: Distribution of HIVE neonates based on HIV-PCR -testing and HIV-PCR -status .............. 47 
Figure 3.3.2: Flowchart representation of infant disposition and timing of HIV-PCR  testing .............. 48 
Figure 3.3.3: Box plot distribution of gestational age for HIV-PCR  + and HIV-PCR -  neonates ........... 50 
Figure 3.3.4: Box plot distribution for birth weights of  HIV-PCR  + and HIV-PCR  - neonates .............. 50 
Figure 3.3.5: Box plot distribution for length-of-stay  of  HIV-PCR + and HIV-PCR - neonates. ............. 51  
  
 8 
Abbreviations  HIV  Human Immunodeficiency Virus PMTCT  Prevention of Mother to Child Transmission HIVEU  HIV Exposed but uninfected  HIV+  HIV infected  HIVU  HIV unexposed HIVE  HIV exposed LBW  Low birth weight PIH  Pregnancy induced hypertension PET  Pre-eclamptic Toxaemia ELBW  Extreme low birth weight ART  Antiretroviral therapy ARV  Antiretroviral ARVE  Antiretroviral exposed ARVU  Antiretroviral under-exposed VLBW  Very low birth weight RDS  Respiratory distress syndrome CLD  Chronic Lung Disease BPD  Bronchopulmonary Dysplasia PDA  Patent ductus arteriosus IVH  Intraventricular Haemorrhage NEC  Necrotising Enterocolitis CMV  Cytomegalovirus TB  Tuberculosis GA  Gestational Age HMD  Hyaline Membrane Disease TTN  Transient tachypnoea of the newborn GBS  Group B Streptococcus EOS  Early Onset Sepsis LOS  Late onset sepsis CI  95% Confidence interval HIV-PCR  Human Immunodeficiency Virus Polymerase chain reaction SGA  Small for gestational age ANC  Antenatal Care CPAP  Continous positive airway pressure VON  Vermont Oxford Network AZT  Zidovudine NVP  Nevirapine HAART  Highly active antiretroviral therapy NMR  Neonatal Mortality Rate RR   Risk Ratio OR   Odds Ratio USA   United States of America IRR  Incident Rate Ratio LRTI   Lower Respiratory Tract Infection aOR  Adjusted Odds Ratio GSH  Groote Schuur Hospital CSF   Cerebrospinal Fluid ROP   Retinopathy of Prematurity UCT  University of Cape Town mARVE Maternal Antiretroviral exposed mARVU Maternal Antiretroviral under-exposed 
 9 
EBM  Exclusive Breast Milk PVL  Periventricular Leukomalacia NIV  Non-invasive Ventilation UK  United Kingdom RCT  Randomised Control Trial WHO  World Health Organisation    
 10 
1. INTRODUCTION AND LITERATURE REVIEW  
BACKGROUND  Maternal HIV infection poses the documented risk of vertical transmission. Effective prevention-of-mother-to-child-transmission (PMTCT) programs have decreased this transmission in developing countries from as high as 48%[1] to less than 5%[2], with a resultant decrease in morbidity and mortality associated with paediatric HIV infection. With the decreasing incidence of perinatal HIV transmission, a growing number of infants and children are falling into the HIV-exposed but uninfected (HIVEU) population. These infants are gaining recognition as a group with their own unique risks in terms of morbidity and mortality, as compared to both HIV infected (HIV+) and HIV unexposed (HIVU) children.  Brennan et al have demonstrated an overall increased risk of mortality by 70%, in a meta-analysis on all-cause mortality between HIV-exposed (HIVE) and HIVU infants and children. This risk lessened after the widespread implementation of PMTCT programmes in 2002, but a significant difference in mortality still remained (<2002: RR 1.73, CI 1.22 – 2.46 and >2002 RR 1.46, CI 1.14 – 1.87) [3]. In a systematic review on mortality and morbidity, among HIVEU and HIVU infants and children under the age of 10 years in Sub-Saharan Africa, Le Roux et al also demonstrated increased overall mortality (RR 1.93, CI 1.17-3.17) [4]. Slogrove et al have evaluated the timing and type of infectious morbidity and mortality in HIVEU infants and children. They concluded firstly, that underlying causes of morbidity and mortality in these infants were the same as the common causes of under-5 mortality, but these tended however to be more severe in presentation. Secondly, that these infants are at an increased risk for invasive streptococcal infections. Thirdly, that the relative increase in morbidity and mortality is most evident between the ages of 2 and 6 months, with HIVEU neonates and HIVU neonates having equally increased risk of morbidity and mortality[5]. In a report from the 2016 annual workshop, established to review the growing evidence in support of this increased risk profile among HIVE infants and children, a summary of the postulated theories as to the yet unexplained aetiology of this increased risk was published. These include innate immune deficits by multiple proposed mechanisms i.e. exposure to antiretrovirals (ARV’s) and HIV viral particles, as well as impaired maternal immunity. Additional factors may include nutritional deficiencies driven by both suboptimal breastfeeding practices and lower socioeconomic status, which often affects HIV-exposed households[6].  In addition to a possible impaired neonatal immune system, antenatal HIV-exposure has risks for infants with regards to higher rates of prematurity[7-9], low birth weight (LBW) [10] and intrauterine growth restriction[9,11,12]. These risks are of particular importance in mothers who have advanced HIV disease[13,14]. A meta-analysis published in 2015 by Xiao et al confirmed this increased risk of LBW (pooled OR 1.73, CI 1.64-1.82) and preterm birth (pooled OR 1.56, CI 1.49-1.63) [15]. 
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An increased risk for pregnancy induced hypertension (PIH) including pre-eclampsia (PET) and eclampsia, has also been described in HIV-exposed pregnancies. The significance of this potential association is that it often results in the delivery of a premature and low birth weight infant. A systematic review of the evidence by Adams et al of HIV-positive mothers and ART with PIH, found the data to be conflicting[16]. Brown et al’s meta-analysis found neither an associated risk with HIV or ART and PIH[17]. However, previously published data from the Groote Schuur Neonatal unit has showed a high prevalence of HIV-exposure among the Extreme Low Birth Weight (ELBW) neonates, most of whom were delivered for maternal hypertensive indications. Although there was no association between HIV and PET, there was a significant association between mothers who had been exposed to antiretroviral therapy (ART) for more than 4 weeks and PET[18].  On their own, very low birth weight (VLBW) neonates have an increased risk of morbidity and mortality. A Johannesburg based study found a survival rate of 86% in neonates with a birth weight of between 1001 and 1500 grams, and as low as 35% for neonates less than 1000grams[19]. Gestational age is also a key determinant of mortality and morbidity risk profiles for these infants, with an inverse relationship between the two[20,21]. Prematurity related complications such as respiratory distress syndrome (RDS) and subsequent bronchopulmonary dysplasia (BPD), patent ductus arteriosus, (PDA), intraventricular haemorrhages (IVH), necrotising enterocolits  (NEC) and sepsis are common contributing factors[21]. The question we subsequently propose, is if all of these risk factors converge to produce an even more vulnerable population of HIVE, premature and very low birth weight neonates during the neonatal period?  
OBJECTIVES  The objective of this literature review was to evaluate the available literature on short-term outcomes of HIV-exposed neonates in terms of mortality and morbidity, specifically with reference to those infants that are premature i.e. <37 weeks gestational age, or VLBW i.e. ≤1500g.  
METHODS  A search was carried out using PubMed (https://www.ncbi.nlm.nih.gov) on 29.1.2017 using the terms HIV-EXPOSED, NEONATE, MORBIDITY in the following search string: (HIV-EXPOSED[All Fields] AND ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND "newborn"[All Fields]) OR "newborn infant"[All Fields] OR "neonate"[All Fields]) AND ("epidemiology"[Subheading] OR "epidemiology"[All Fields] OR "morbidity"[All Fields] OR "morbidity"[MeSH Terms])) AND "infant, newborn"[MeSH Terms].  
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This yielded 210 articles. 5 were immediately excluded because they were not published in English.  Primarily, articles were required to report outcomes of HIV-exposed and HIVEU neonates, either descriptively or by comparison with an unexposed cohort. Outcomes needed to specifically be focused on those relevant to short-term neonatal admission diagnosis. This included mortality and morbidity in the form of sepsis, jaundice, respiratory complications and NEC.  Articles were excluded if their title or abstract clearly did not meet inclusion criteria.  When this was less clear the methods and results sections were scrutinised in the full text to evaluate for inclusion. Studies were excluded if they looked at PMTCT outcomes, effects of ARV’s or evidence of altered immune function based on haematological, serological or vaccine response studies. Studies were also excluded if they looked at long-term outcomes that are beyond the scope of the neonatal period, including growth and development, and outcomes based on feeding and nutritional interventions. Birth outcomes studies were reviewed separately and less formally for the introduction of this review and were also excluded. Studies that looked at congenital abnormalities and infections specifically Hepatitis B, Syphilis, CMV and TB were not included in our review. Although certainly relevant in terms of neonatal morbidity, their impact is too specific and beyond the scope of this review.  The remaining studies were excluded for the following reasons 
• 3 reviewed outcomes based on specific interventions including, probiotics and Co-Trimoxazole prophylaxis.  
• 2 were practice guidelines and management reviews  An additional 2 studies were identified as appropriate based on reference lists from the included studies.  The final 21 articles were reviewed in full text and findings were summarised in Tables 
1.1 – 1.5. 
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Figure 1.1: Flow diagram of article selection process 
 
RESULTS  The 21 articles were published between 1991 and 2015 with the majority of the literature (16/21) published after 2010.  Five reports came from outside of Africa: 4 of these from developed nations including the USA, France and Belgium[10,22-24] and 1 from Latin America[25]. The remaining 16 were published out of Sub-Saharan Africa with 7/16 coming from South Africa. The 2 studies from Zimbabwe reported findings from the same database (ZVITAMBO trial) [26] although Koyanagi et al reported morbidity data and Marinda et al reported on mortality[27,28]. Twelve out of 21 were prospective studies; 7 primary analyses [10,29-34] and 5 secondary[25,35-38]. The remaining 9 were retrospective; 7 primary[10,29,30,32-34,39] and 2 secondary analyses[27,28]. Four studies were case control cohorts[23,32,38,40]. Thirteen studies focused on mostly term babies, 6 on premature (<37 weeks) [23,34,40-42] and 2 did not report gestational age[29,36]. Thirteen studies reviewed mostly normal birth weight infants (>2500g) and 2 reviewed predominantly LBW between 1500g and 2500g[29,34]. VLBW infants i.e. 1000-1500g, were referenced as between 3% and 63% in 4 articles[10,29,30,34] and additionally represented the average weight of the 5 cohorts that evaluated NEC[23,40-43]. Only 1 study referenced ELBW infants (<1000g) as 8% of the cohort[34]. One study did not document birth weights[24].  
MORTALITY Seven studies reported on mortality (Table 1.1) [28,29,32,34-36,38].  All 7 were published out of Sub-Saharan Africa and sample sizes ranged from 70 to 13792. Five cohorts focused on mostly term and normal birth weight neonates[28,32,35,36,38]. Two looked at a largely preterm (median GA 34 weeks) and LBW infants[29,34].  Ades et al published a Neonatal Mortality Rate (NMR) of 37/1000 live births[35] while Kourtis et al reported a rate of 0.056/person year[36]. Four of the 5 comparative studies did not find a difference in mortality between HIVE and HIVU infants[29,32,34,38].  
• PMTCT, ARV, vaccine responses, immune function, growth and devevelopment, feeding, nutritionn = 205: EXCLUDE 153
• Birth outcomes, congenital abnormality, Congenital infections
n = 52: EXCLUDE 19 • 3 =interventional
• 2 = practice and management
• 1 = outcomes outside neonatal periodn = 33: EXCLUDE 6
• 2 added from reference reviews
n = 19: INCLUDE 2 TOTAL              n = 21
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Only Marinda et al reported a difference in mortality rates between HIV+, HIVEU and HIVU infants. They published a 30-day mortality proportion of 1.9% in HIVEU and 0.7% in HIVU infants, and statistically compared mortality at 8 weeks of age, demonstrating an increased risk in HIVEU compared to HIVU (RR 2.8 CI 2.1 – 3.9) [28]. Monebenimp et al found prematurity and LBW to be risk factors for mortality but in both HIVE and HIVU infants[32]. Kourtis et al found only LBW to be associated with neonatal death in their cohort[36]. Ades et al found multiple associations with neonatal mortality in their cohort (n=351), but only prematurity was associated with mortality on multivariate analysis (Table 1.1) [29,35]. 
ALL CAUSE MORBIDITY Only 3 articles looked at all cause morbidity (Table1. 2) [27,29,31]. All 3 were published from Sub-Saharan Africa between 2005 and 2014. Sample sizes ranged from 70 – 12937. One study compared HIVE vs. HIVU[29] and two studies compared HIVEU vs. HIVU[27,39]. Two studies focused on predominantly term and normal birth weight infants[27,31]. Adhikari et al did not report gestational age for their cohort but most babies were less than 2.5kg (90% and 87% for HIVE and HIVU respectively) with a large proportion of them falling into the VLBW category (63% and 45%). In addition the most common admission diagnosis was hyaline membrane disease (HMD), so we can postulate that the cohort was predominantly premature[29]. Only the Zimbabwe study reported a difference in all-cause morbidity. Incidentally this was also the earliest study, with data captured between 1997 and 2000. They reported more all-cause sick visits between HIVEU and HIVU infants, incident rate ratio (IRR) 1.2, CI 1.1-1.4. Presentation with a lower respiratory tract infection (LRTI) was the only specific clinical cause to explain this difference with an IRR of 1.6, CI 1.1-2.3[27]. The remaining 2 studies reported no difference in all cause morbidity[29,31].  
SPECIFIC MORBIDITY The remaining 12 articles looked at specific morbidity causes. One article looked at jaundice requiring phototherapy in a small numbered (n = 149) prospective study comparing incidence, and found that HIVE was protective in terms of developing supra-treatment jaundice. This study was poorly powered however and is limited in terms of its application (Table 1.3) [33].  Two studies looked at Respiratory Distress Syndrome (RDS) [10,25]. One was published in 1997 out of the USA and one in 2011 from Latin America. They both looked at prospective cohorts of largely term and normal birth weight infants, and they both only had cohorts of HIVE infants thus do not have good comparative data. The later Latin American study quantified respiratory morbidity as part of the secondary outcomes from within a larger study, which compared respiratory outcomes based on mode of delivery in an HIVE cohort. They reported a morbidity of 7.5%, mostly due to RDS and transient tachypnoea of the newborn (TTN) [25]. The earlier USA based study was more helpful by comparing their numbers to expected values for the population, but observed no difference in respiratory morbidity among HIVE neonates (Table 1.3) [10].  
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Four studies on sepsis were published between 2010 and 2015 (Table 1.4) [22,24,30,37]. Two of these were published out of the same clinical research unit in Belgium and with some overlap of the time period. The first looked at incidence of Group B Streptococcal (GBS) infection and the second at all-cause severe infections, albeit in children under 1 year of age[22,24]. The remaining 2 reports were published out of Baragwanath Hospital in Soweto, also with overlap in the data collection years. Again one report focused on all-cause sepsis, however restricted to the neonatal period, and the second looked at evidence for increased GBS disease[30,37]. Sample sizes ranged between 21 and 4108, and all 4 studies looked at mostly term infants.  Only one study, Cutland et al , had appropriate data for all-cause sepsis morbidity in the neonatal period[37], as the Belgium study only reported incidence at the end of the first year of life[22]. The Johannesburg based study, reflective of a large cohort of 4108 neonates, prospective in nature and well matched in terms of maternal and neonatal characteristics, reported a borderline increased incidence of early onset culture-positive sepsis in HIVE compared to HIVU neonates (p=0.05). No difference was detected between clinically suspected early onset sepsis (EOS) or overall EOS.  Further analysis of confirmed HIVEU vs. HIVU neonates (n=2432) actually showed a decreased incidence of clinically suspected and overall EOS, which is contrary to what is hypothesised. No difference between either the HIVE or HIVEU groups compared to HIVU neonates was found with regards to incidence of late onset sepsis (LOS) i.e. after day 3 of life[37]. Three studies found evidence that HIVE babies get more GBS sepsis. Specifically looking at HIVEU babies, Epalza et al showed an overall RR of 19.6 (CI 7.5 – 51.7) and specifically an increased risk for late onset disease (RR 125.2; CI 26.3-620.2) [24]. This evidence is limited by very small numbers and not well powered (n = 21). Adler et al also looked at HIVEU infants and showed a 13-times increased incidence in GBS sepsis by comparing their findings to the reported population incidence[22]. Cutland et al found both increased overall risk (RR 2.25, CI 1.84 – 2.76) as well as specific increased risk for late onset GBS disease i.e. HIVE 58.1% vs. HIVU 41.9%, p=0.004. This data reports essentially HIVE babies as opposed to HIVEU as PCR results were only available for 28% of the sample[30].  Risk factors reported for sepsis in the neonatal period included prematurity[22,24] and small for gestational age (SGA) [24]. Cutland et al reported an increased case fatality rate for VLBW babies and a GA <33 weeks[30]. Epalza et al reported a trend for increased severity of disease (meningitis and septic shock) among HIVEU babies, as did Cutland et al (meningitis and bacteraemia) [24,30].  Five of the studies looked at NEC (Table 1.5). Only one study was published from a developed nation i.e. France and was also the earliest study from 2005[23]. The remaining 4 studies, published between 2010 and 2014, were all from South Africa (1 from Johannesburg, 3 from Cape Town) [40-43]. All of the cohorts comprised of premature (30–31 weeks) and VLBW neonates (1.2 – 1.6kg). All of the studies were retrospective and small in size ranging from n=37 to n=337. Two of the studies compared incidence of NEC between HIVE and HIVU infants[23,40]. Angura et al found no difference but Desfrere et al found an increased risk (aOR 6.63, CI 1.26 – 35).  When comparing methodology and cohorts, significant differences included the time period during which data was 
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captured (late 1990’s/early 2000’s for Desfrere and mid-2000’s for Angura), the prevalence of HIV in the population (low for Desfrere and high for Angura) and feeding [Desfrere babies first fed slightly later than Angura i.e. day 4 and day 2 respectively, but Desfrere babies received more breast milk than Angura (88% vs. 58%)].  None of the four studies that looked at clinical outcome or extent of disease found any differences between HIVE and HIVU[40-43], but Arnold et al did report an increase in post-operative sepsis in HIVE neonates compared to HIVU (41% vs. 16%, p=0.03) [41]. Four studies reported on mortality with 2 reporting no difference[41] while Karpelowsky reported increased mortality (OR 4.8, p =0.05) [43], as did Chokoe (20% vs. 83%, p = 0.0002) [42]. Both of these studies were limited by the fact that they were retrospective reviews, did not adjust outcomes for other confounding factors and had small sample sizes (n =70 and 37 respectively). Comparing the evidence of the studies that reported no difference, Arnold et al and Angura et al, the same limitations applied with the exception of Angura who had the largest cohort, n = 330[40,41]. 
 
DISCUSSION  Data on outcomes of HIVE neonates is limited. The literature is comprised of prospective and retrospective reviews made up of relatively small number cohorts, with the best level of evidence being a single prospective matched case-control study[38]. In addition the literature predominantly reflects cohorts of term and normal birth weight babies. This probably stems from the majority of the work being published out of Sub-Saharan Africa. Despite the high prevalence of HIV in this region, the mortality of premature and VLBW infants is significant, which makes it difficult to find adequate numbers of these babies to sample.  Outcomes relating to NEC - a pathology almost exclusively seen in premature infants - is the exception with regards to birth weight and gestational age sampling, however the cohort numbers are small.  Prematurity is reported as a risk factor for mortality and sepsis among HIVE neonates in the reports we reviewed. On closer scrutinisation of this literature, Monebenimp et al’s[32] findings on increased mortality risk relates to both HIVE as well as HIVU neonates and Ades et al[35] is descriptive data from a cohort of only HIVE infants. It is therefore difficult to determine if this risk does not reflect the known risk of prematurity on its own. Regarding birth weight, Cutland et al’s[30] observation of HIV-exposed VLBW neonates having increased mortality is limited to those who developed GBS sepsis. The only other study that commented on LBW as a risk factor for mortality among HIVE neonates was Kourtis et al[36], but being a descriptive study, it possibly again reflects the known increased risk of the LBW population. The quality and relevance of the evidence regarding neonatal jaundice and RDS limits our ability to draw any valuable conclusions. (Table 1.3) Only one study suggests no increased morbidity related to RDS, but this is only relevant to term neonates[10].  Ades et al’s[35] reported neonatal mortality rate of 37/1000 live births is much higher than the local Ugandan NMR (23.1 – 20.4/1000) for the time period between 2009 and 
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2012 during which the data was captured[44]. Marinda et al also reported an increased mortality rate[28]. Their study, although well designed and with impressive numbers, only allows us to assume a significant 28-day mortality based on the statistics at 8 weeks of life. A second consideration is that the data reflects HIV-exposure prior to the widespread use of maternal ARV’s and PMTCT programmes and may now be outdated[28]. We have seen from Le Roux et al’s[4] postulations from their systematic review, that better maternal health may minimise the risk of mortality to their infants. This is supported by Brennan et al’s[3] findings of decreased mortality in the post-ARV era. Four out of the 5[29,32,34,38] comparative studies did not show an increased mortality, with at least 2 of the 4 studies reflective of a largely preterm cohort[29,34]. The evidence as such seems to favour no difference in mortality (Table 1.1). Two out of 3 studies on all-cause morbidity found no difference including one that reflects an assumed cohort of preterm infants[29,31]. Koyanagi’s et al’s study[27] which did report an increased morbidity represents the same large Zimbabwe cohort as Marinda et al and so the pre-ARV era considerations of expected poorer outcomes apply equally 
(Table 1.2). Three out of the 4 studies on sepsis reported increased risk of sepsis in HIVE neonates, but all three specifically looked at GBS. Two of the studies convincingly excluded infections in HIV positive infants but one is poorly powered (n = 21) [24] and the second is a descriptive study comparing an incidence rate with that of the general population[22]. The 2015 study from Baragwanath[30] has HIV PCR data available for only 28% of their HIVE neonates, thus is limited by it’s inability to accurately distinguish HIV-infected and HIVEU infants. This is especially relevant given that an earlier study from this unit found a clear increase in overall sepsis in HIV positive neonates[37]. A second limitation of this data is that the overall incidence of GBS was increased in the study (2.72 cases/1000 live births) compared to global (0.53 cases/1000) and African (1.21 cases/1000) estimates, reported in a meta-analysis on GBS sepsis, between 2000 – 2011[45]. Consequently, the increased GBS incidence reflected may be prone to population bias. Two studies[24,30] show this increased GBS sepsis risk is reflected in the late onset period and although Cutland et al[30] shows both EOS and LOS have increased risk; it is quantitatively higher in late disease (RR for EOS 1.69, CI 1.28 – 2.24, RR for LOS 3.18, CI 2.34 – 4.36, Table 1.4).  There was 1 study on all-cause sepsis and that refuted the hypothesis of an increased risk in HIVEU neonates. It reported a decreased incidence of clinically suspected early onset sepsis between HIVEU neonates compared to HIVU (20.6 vs. 33.7 per 1000 births; p = .046), and no difference in late onset disease (5.8 vs. 4.1; p = 0.563). However, in the same cohort, when looking at the HIVE neonates i.e. disregarding neonatal HIV status, they reported an increased incidence of culture positive EOS among HIVE neonates compared to HIVU[37]. Some key issues to note in this review include;  
− a very small number of neonates actually had positive cultures (0.3%), which may affect the validity of this outcome.  
− Significantly more of the HIV+ neonates had EOS compared to the HIVU neonates (134 vs. 21.5 per 1000 births, p = 0.046), which might account for the increased sepsis in the HIVE cohort. 
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− The neonates in the “clinical sepsis” group were possibly oversampled based on excessively broad criteria for sepsis.  
− This cohort was at risk of sample bias in favour of less sepsis, as only 4% of the cohort was premature, a number well below the incidence of the unit. We did not review the inclusion and exclusion criteria of the original maternal cohort for the primary analysis that may have predisposed to this selection bias[37]. 
(Table 1.4) Despite the literature on NEC being relevant to premature and VLBW infants it is limited by small sample sizes (n = 37 -330) and retrospective data. The trend for similar presentation of disease between HIVE and HIVU infants seems constant in the articles, and one study showed an increased risk for post-operative sepsis [41]. Regarding incidence of disease and mortality it is divided (Table 1.5).  
CONCLUSION  There is good evidence that older HIVEU infants and children have increased morbidity and mortality as compared to their HIVU counterparts, however it remains unclear as to the underlying aetiology of this increased risk.  The literature on HIVE neonates is limited to cohort studies, with poor representation of high risk VLBW and premature neonates. Regarding specific outcomes, there is only 1 comparative study on respiratory outcomes and it focuses on term neonates. The evidence pertaining to increased sepsis in HIVE neonates is almost exclusively related to GBS infections. While the NEC literature is pertinent to premature and VLBW neonates, it is limited in terms of study design and small sample sizes. Overall however, the available evidence does not favour a hypothesis of increased mortality and all-cause morbidity between HIVE and HIVU neonates.  There is a need for well-powered evidence comparing HIVE and HIVU premature and LBW infants looking at short-term neonatal outcomes. Of interest is mortality, differences in gestation, birth weight and growth restriction as well as morbidity due to respiratory distress, sepsis and NEC.  
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Table 1.1: Summary of studies on mortality  
 
GA = gestational age, HIVE = HIV exposed, HIVU = HIV unexposed, LBW = low birth weight (< 2500g), VLBW = very low birth weight (1000g – 1500g), ELBW = extremely low birth weight (<1000g), HIVEU = HIV exposed but uninfected, ART 
= antiretroviral therapy, BWT = birth weight 
# 
FIRST   
AUTHOR TITLE 
PUBLISH 
DATE STUDY DESIGN LOCATION MAIN OUTCOME SAMPLE SIZE GA 
BIRTH 
WEIGHT 
MORTALITY 
OUTCOME 
MORBIDITY 
OUTCOME OTHER 
39. Zash RM 
Risk factors for mortality among 
HIV-exposed and HIV unexposed 
infants admitted to a neonatal care 
unit in Botswana 2014 
Prospective.  
Secondary analysis. 
Comparative. 
Botswana: 
2008/2009 
Risk factors for neonatal 
mortality 
n = 449.                   
HIVE n=128 (29%) 
HIVU n=272 (60%) 
unknown status n = 49 
(11%) 
Median GA 
34 weeks 
LBW 32%  
VLBW 23% 
ELBW 8% 
No difference between 
HIVE (27%) and HIVU 
(20%) p = 0.19 
Discharge 
diagnoses the 
same.              
No difference in 
sepsis. (p =0.92)    
35. Marinda E 
Child mortality according to 
maternal and infant HIV status in 
Zimbabwe 2007 
Retrospective.  
Secondary analysis of 
ZVITAMBO trial data. 
Comparative. 
Zimbabwe: 
1997-2000 
Compare mortality rates for 
HIV+/HIVEU/HIVU infants in 
the first 2 years 
n = 13 792.            
HIVEU: 3135             
HIVU: 9510               
HIV+: 1147 
Mean GA   
39 weeks. 
LBW      
HIVEU 15% 
HIVU 12% 
<1500G 
excluded 
30day deaths:  
HIVEU 1.9%  
HIVU 0.7%           
8-week risk of mortality 
HIVEU vs. HIVU  
RR 2.8 (2.1 - 3.9)     
40. Ades V 
Neonatal mortality in HIV-exposed 
infants born to women receiving 
combination antiretroviral therapy 
in rural Uganda 2013 
Prospective. Secondary 
analysis of PMTCT study. 
Descriptive. 
Uganda: 
2009-2012 
Assess risk factors for 
neonatal morbidity in HIVE 
infants n = 351 
Median GA  
39 weeks LBW 20% 
Neonatal mortality rate 
37/1000 live births   
ASSOCIATIONS WITH 
MORTALITY    
Univariate analysis: 
low GA, LBW and 
shorter duration of 
maternal ART. 
Multivariate analysis = 
low GA.  
41. Kourtis AP 
Health outcomes in HIV-exposed 
uninfected infants 2013 
Prospective. Secondary 
analysis of BAN study 
(Breastfeeding, 
Antiretrovirals and 
Nutrition). Descriptive. 
Malawi: 
2004-2010 
Evaluate effect of prognostic 
factors on infant morbidity 
and mortality n = 2250 
not 
documented 
LBW 7%  
<2000g 
excluded 
Neonatal mortality rate 
of 0.056/ person year   
Only association with 
death was LBW 
(<2500g) 
37. Monebenimp F 
HIV exposure related newborn 
morbidity and mortality in the 
University Teaching Hospital of 
Yaounde, Cameroon 2011 
Prospective. Primary 
analysis. Case-control 
Cameroon 
2006/2007 
HIVE related to neonatal 
morbidity and mortality 
n = 240.                    
HIVE 80                    
HIVU 160 
preterm 
24% 
LBW  21% 
Mean bwt 
2.9kg No difference p = 0.52   
On univariate, analysis 
prematurity and LBW 
associated with HIVE, 
not on multivariate 
analysis. 
42. Lepage P 
Perinatal transmission of HIV-1: lack 
of impact of maternal HIV infection 
on characteristics of live births and 
on neonatal mortality in Kigali, 
Rwanda 1991 
Prospective. Primary 
analysis. Matched case-
control. 
Rwanda: 
1988-1989 
Uncertain - Only abstract 
available: Part of a perinatal 
transmission study 
n = 436.                    
HIVE 218                  
HIVU 218 
Median GA 
39 weeks LBW 20% No difference     
29. Adhikari M 
The HIV-1 exposed neonate: 
outcome of intensive care 
management in the first week of 
life 2005 
Prospective. Primary 
analysis. Comparative. 
Durban: 
2000/2001 
Compare short and medium-
term prognosis between 
HIVE and HIVU neonates 
(excluded if mom received 
nevirapine) 
n=70.                           
HIVE 30                     
HIVU 40   
not 
reported 
HIVE:       LBW 
90% 
VLBW 63% 
HIVU:   
LBW 87% VLBW 
45% No difference p = 0.42 
No clinical 
difference 
between the 
two groups 
Majority of babies 
were VLBW and 
admitted with HMD so 
probably a mostly 
preterm cohort. 
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Table 1.2: Summary of studies on all-cause morbidity 
# 
FIRST 
AUTHOR TITLE 
DATE 
PUBLISH STUDY DESIGN LOCATION MAIN OUTCOME SAMPLE SIZE GA 
BIRTH 
WEIGHT 
MORTALITY 
OUTCOME 
MORBIDITY 
OUTCOME OTHER 
34. Koyanagi A 
Morbidity among HIV exposed but 
uninfected, HIV infected and HIV 
unexposed infants in Zimbabwe 
before availability of HAART 2011 
Retrospective. Secondary 
analysis of ZVITAMBO 
study. Comparative. 
Zimbabwe: 
1997 - 2000 
Evaluate rates of total and 
cause specific sick clinic visits 
or hospitalisations up to 2 
years age. 
n= 12 937           
HIVEU 2661          
HIVU 9207              
HIV+ 1069 
Preterm 
6.7%  
Mean BWT 
3000g <1500g 
excluded   
Increased neonatal 
all cause sick clinic 
visits               
IRR 1.2 (1.1-1.4)  
LRTI IRR 1.6 (1.1 - 2.3) 
Increased all cause 
admissions   
IRR 1.5 (1.2 - 2.0);  
LRTI significant  
IRR 2.7 (1.6 - 4.7) 
36. Moraleda C 
Impact of HIV exposure on health 
outcomes in HIV-negative infants 
born to HIV-positive mothers 2014 
Prospective. Primary 
analysis. Comparative. 
Mozambique: 
2008 - 2009 
Evaluate impact of maternal 
HIV status on child health. 
n=318.  
HIVEU 158   
HIVU 160 
Median 
GA 39 
weeks 
LBW 5.5% 
Median BWT 
3000g   
No difference in OPD 
visits or hospital 
admissions in first 
month between HIVE 
and HIVEU.    
29. Adhikari M 
The HIV-1 exposed neonate: 
outcome of intensive care 
management in the first week of 
life 2005 
Prospective. Primary 
analysis. Comparative. 
Durban: 
2000/2001 
Compare short and medium-
term prognosis between 
HIVE and HIVU neonates 
(excluded if mom received 
nevirapine) 
n=70.  
HIVE 30  
HIVU 40   
not 
reported 
HIVE:  
LBW 90%  
VLBW 63% 
HIVU:  
LBW 87%  
VLBW 45% No difference 
No clinical difference 
between the two 
groups 
Majority of babies 
were VLBW and 
admitted with HMD so 
probably a mostly 
preterm cohort.  GA = gestational age, HIVEU = HIV exposed yet uninfected, HIVU = HIV unexposed, HIV+ = HIV positive, BWT = birth weight, IRR = incidence risk ratio, LRTI = lower respiratory tract infection, LBW = low birth weight, OPD = outpatients’ department, HIVE = HIV exposed, VLBW = very low birth weight, HMD = hyaline membrane disease.   
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Table 1.3: Summary of studies on neonatal jaundice and respiratory distress syndrome 
# FIRST AUTHOR TITLE 
DATE 
PUBLISH STUDY DESIGN LOCATION MAIN OUTCOME SAMPLE SIZE GA 
BIRTH 
WEIGHT MORTALITY OUTCOME 
MORBIDITY 
OUTCOME OTHER 
38. Nakanga W 
Supra-treatment threshold 
neonatal jaundice: Incidence in HIV-
exposed compared to non-exposed 
neonates at Queen Elizabeth 
Central Hospital in Blantyre, 
Malawi. 2015 
Prospective. Primary 
analysis. Comparative. 
Malawi: 4 
weeks 
Sept/Oct 
2013 
Test hypothesis that HIVE 
neonates have higher 
incidence of neonatal 
jaundice 
n=149.  
HIVE 17  
HIVU 132 
Premature 
31%  LBW 43%   
HIVU = more 
jaundice. 
(81% vs. 47%, 
p <0.0001).   
25. Kreitchmann R 
Mode of delivery and neonatal 
respiratory morbidity among HIV-
exposed newborns in Latin America 
and the Caribbean: NISDI perinatal-
LILAC studies. 2011 
Prospective. Secondary 
analysis. Descriptive. 
Latin 
America/ 
Caribbean: 
2002- 2009 
Assess effect of mode of 
delivery on neonatal 
respiratory distress in HIVE 
infants n = 1443 
Premature 
9.7%  LBW 10%   
Incidence 
7.5% mostly 
due to RDS 
and TTN   
10. Martin R 
Incidence of premature birth and 
neonatal respiratory disease in 
infants of HIV positive mothers 1997 
Prospective. Primary 
analysis. Descriptive 
(compared to general 
population) 
USA: 1990 - 
1994 
1. Characterize rates of 
prematurity and LBW in 
cohort of HIVE infants.  
2. Determine spectrum, 
incidence and severity of 
respiratory disease n = 600 
Premature 
19%  
LBW 18% 
VLBW 3%   
Respiratory 
outcomes as 
expected for 
the general 
population    GA = gestational age, HIVE = HIV exposed, HIVU = HIV unexposed, LBW = low birth weight, HIVU = HIV unexposed, RDS = respiratory distress syndrome, TTN = transient tachypnoea of the newborn, VLBW = very low birth weight.      
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Table 1.4: Summary of studies on sepsis 
# FIRST AUTHOR TITLE 
DATE 
PUBLISH STUDY DESIGN LOCATION MAIN OUTCOME SAMPLE SIZE GA BIRTH WEIGHT 
MORTALITY 
OUTCOME MORBIDITY OUTCOME OTHER 
24. Epalza C 
High incidence of invasive group B 
streptococcal infections in HIV-
exposed uninfected infants 2010 
Retrospective. Primary 
analysis. Comparative. 
Brussels: 2001 
- 2008 
Characterise and compare 
GBS infections in HIVEU 
infants with HIVU infants 
(recruited up to 90days life) 
n=21.  
HIVEU 5    
HIVU 16 PT 37%  
not 
documented   
Increased risk in HIVEU –  
RR for GBS overall 19.6 (7.5 
- 51.7)  
EOD not statistically 
different.  
LOD =  
125.2 ( 26.3 - 620.2) 
More PT and SGA 
in the HIVE 
group. Tended 
towards more 
severe in HIVE. 
22. Adler C 
Severe Infections in HIV-Exposed 
Uninfected Infants Born in a 
European Country. 2015 
Retrospective. Primary 
analysis. Descriptive 
(compared to general 
population) 
Brussels: 1985 
- 2006 
Examine incidence and risk 
factors for all cause severe 
infection in HIVEU cohort 
(data representative of first 
year of life) n=537 PT 11.6%  
mean weight 
3037g 15% 
LBW   
GBS infection 13x higher 
than general population.   
PTB = risk factor in the 
neonatal period. 
(aOR 21.34; 7.13 - 63.93)   
30. Cutland CL 
Increased risk for GBS sepsis in 
young infants exposed to HIV, 
SOWETO, SOUTH AFRICA. 2015 
Prospective. Primary 
analysis. Comparative. 
Soweto, JHB: 
2004 - 2008 
Examine clinical and 
epidemiological 
characteristics of GBS sepsis 
in a population with high HIV 
prevalence. (recruited up to 
90 days) n = 327 
PT 27%;    
70% < 33 weeks 
Median weight 
2800g  
LBW 36%   
VLBW 11%   
Overall RR 2.25 (1.84 - 2.76) times increased 
invasive GBS in HIVE vs. HIVU.  
EOD: RR 1.69, CI 1.28 – 2.24   
LOD: RR 3.18, CI 2.34 – 4.36  
Bacteraemia and meningitis increased in HIVE 
infants.  
VLBW and <33 weeks = increased case fatality 
rate.  
HIVE more likely to have LOD than EOD. 
26. Cutland CL 
Maternal HIV infection and vertical 
transmission of pathogenic bacteria 2012 
Prospective. Secondary 
analysis. Comparative. 
Soweto, JHB: 
2004 - 2007 
Examine effect of maternal 
HIV infection on prevalence 
of pathogens in mothers and 
subsequent transmission 
and sepsis rates in the 
neonates n = 2432 - 4108 
4% PT.  
Significant 
difference in HIVE 
(6%) vs. HIVU 
(3%) 
Median weight 
3130g   
Borderline significant increased culture 
confirmed EOD in HIVE (p=0.05)   
HIVEU had lower incidence compared to HIVU  
(p=0.045).  
LOD: no difference   GA = gestational age, GBS = group B streptococcus, HIVEU = HIV exposed uninfected, HIVU = HIV unexposed, PT = preterm, RR = risk ratio, EOD = early onset disease, LOD = late onset disease, SGA = small for gestational age, HIVE = HIV exposed, PTB = preterm birth, aOR = adjusted odds ratio, JHB = Johannesburg, LBW = low birth weight, VLBW = very low birth weight,    
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Table 1.5: Summary of studies on necrotising enterocolitis 
# FIRST AUTHOR TITLE 
DATE 
PUBLISH STUDY DESIGN LOCATION MAIN OUTCOME SAMPLE SIZE GA BIRTH WEIGHT 
MORTALITY 
OUTCOME 
MORBIDITY 
OUTCOME OTHER 
31. Karpelowsky JS 
Effect of maternal human 
immunodeficiency virus status on 
the outcome of neonates with 
necrotizing enterocolitis 2010 
Retrospective. Primary 
analysis. Comparative.  
Cape Town: 
1998 - 2008 
Assess the effect of HIV 
exposure on survival and 
extent of NEC disease in 
patients requiring surgery n = 70 
Mean GA 
31.6 weeks 
Mean weight 
1417g 
Increased mortality 
in HIVE   
OR 4.8, p = 0.05 
No difference in 
extent of disease   
27. Angura P 
Risk factors for necrotising 
enterocolitis in an HIV-endemic 
region. 2014 
Retrospective. Primary 
analysis. Case control: 
NEC vs. non-NEC. 
JHB:  
2005 - 2008 
Comparative study to assess 
risk factors for NEC in 
premature infants with 
grade 2 or 3 NEC. n = 330 
Median GA 
31 weeks 
Median weight 
1370g HIVE not a risk factor. Clinical presentation and mortality similar 
28. Arnold M 
HIV exposure does not worsen 
outcome in stage III necrotizing 
enterocolitis with current 
treatment protocols 2012 
Retrospective. Primary 
analysis. Comparative. 
Cape Town.  
4 years not 
specified 
 To evaluate the disease 
presentation, progression 
and outcome of stage III NEC 
among HIV-exposed 
compared with unexposed 
infants 
 n = 87  
HIVE 17    
HIVU 70 
Mean GA   
30 weeks 
Mean weight 
1300g 
No difference in 
mortality 
No difference in 
presentation. 
Increased  
post-op sepsis 
41% vs. 16%,  
p = 0.03   
23. Desfrere L 
Increased incidence of necrotizing 
enterocolitis in premature infants 
born to HIV-positive mothers 2005 
Retrospective. Primary 
analysis. Case control. 
Paris:  
1995 - 2003 
Evaluate if premature birth 
and HIV-exposure is an 
independent risk factor for 
NEC 
n=237.  
79 NEC   
Controls 158  
Mean PMA 
30 weeks 
Mean weight 
1300g   
Multivariate 
analysis = HIVE 
OR 6.63 (1.26 - 
35) for NEC   
32. Chokoe MJ 
Necrotizing Enterocolitis in HIV-
Exposed and Nonexposed Infants: 
Clinical Presentation and 
Histopathological Features 2012 
Retrospective. Primary 
analysis. Comparative. 
Tygerberg: 
1992 - 2008 
Compare clinical and 
histopathological features 
between HIVE and HIVU 
infants with NEC 
n=37.  
HIVE = 10 
Mean GA   
31 weeks 
Mean weight 
HIVE 1200g 
HIVU 1600g 
Increased mortality 
in HIVE   
80% mortality vs. 
15%, p = 0.0002 
No clinical or 
histopathological 
difference    GA = gestational age, NEC = necrotising enterocolitis, HIVE = HIV exposed, OR = odds ratio, JHB = Johannesburg, HIVU = HIV unexposed, PMA = post-menstrual age.   
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2. METHODS  
AIMS AND OBJECTIVES The aim of the study is to determine if there is an increased morbidity profile or mortality among premature, HIV exposed, very low birth weight neonates (VLBW).  To do this,  a comparison between a cohort of HIV exposed and HIV unexposed  VLBW neonates was done focusing on the following outcomes:  1. PRIMARY OBJECTIVE:  To determine if there are any differences between the two groups in terms of: i. Anthropometry and gestational age ii. Maternal factors including antenatal care and receipt of steroids, maternal morbidity including hypertension and chorioamnionitis, and lastly the delivery method i.e. vaginal vs. caesarean section iii. Mortality before discharge home iv. Morbidity before discharge including 
• Respiratory support and subsequent development of chronic lung disease 
• Necrotising Enterocolitis (NEC) 
• Intraventricular haemorrhage (IVH) and Periventricular Leukomalacia (PVL) 
• Sepsis v. Length of Stay vi. Feeding method at discharge  2. SECONDARY OBJECTIVE   i. To evaluate the impact of adequate maternal antiretroviral therapy (defined as > 8 weeks of therapy prior to delivery) on the primary outcomes in HIV exposed neonates.  ii. To determine the HIV transmission rate in the exposed group and to compare the primary outcomes of those neonates who tested HIV-positive to those who were exposed but uninfected.   
STUDY DESIGN A retrospective review of infants born weighing ≤1500g (VLBW) admitted to the neonatal unit at Groote Schuur Hospital (GSH) in Cape Town, South Africa between January 2012 and December 2014 was conducted. Based on the latest antenatal surveillance reports, the HIV prevalence within this area - the Western Cape Metro - is 21.7%,[1] which is higher than the GSH prevalence of 16%.[2] GSH is a tertiary level facility attached to the University of Cape Town (UCT) Faculty of Health Sciences. It is a 
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government funded public healthcare facility that provides specialist services to patients within the Western Metro municipal district of Cape Town. It is the preferred delivery and admission facility for neonates with an expected birth weight of ≤1200g. The neonatal unit admits approximately 2000 infants per year of which roughly 500 are VLBW.   
DATA CAPTURING Maternal demographics and neonatal outcomes are recorded for all VLBW infants admitted to the unit for the Vermont Oxford Network (VON) Database. This is an international collaborative neonatal database with over a thousand units from 30 countries that contribute. Neonatal outcomes reflect events that occurred from the time of admission until the date of death or discharge home, including events during transfer to another facility. Patient data submitted to the database are de-identified and confidential. [3]  Definitions of these data points were taken from the Vermont Manual of Operations[4] and are explained in more detail in appendix B.  Maternal demographics included:  
• Ethnicity:  
• Antenatal care (ANC):  
• Chorioamnionitis 
• Antenatal steroids  
• Maternal hypertension  
• Type of delivery  Neonatal outcomes included:  
• Birth Weight 
• Gestational age 
• Length of stay  
• Death 
• Delivery room resuscitation  
• Respiratory support  
• Culture proven sepsis 
• NEC 
• Surgery 
• Intraventricular haemorrhage and cystic periventricular leukomalacia  We also included the type of feeding at discharge i.e. exclusive breast milk, formula feeding or mixed. Analysis of these neonates was restricted to only include the neonates who were discharged home directly from our unit. We excluded neonates who died (as most of them were not fed in the 24 hours prior to their death) and those who were transferred out. Neonates are often transferred to a step-down unit for weight gain prior to discharge and are still receiving breast milk fortification with FM85. This may have skewed the analysis in favour of mixed feeding if this data had not been appropriately updated when the neonate was discharged home.  
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 HIV related information, which is not captured on the VON database, was obtained from folder review of neonates identified as being HIV-exposed from the Maternity Centre Prevention of Mother to Child Transmission (PMTCT) register.  These variables included 
• Maternal ARV exposure including duration and type i.e. AZT/NVP prophylaxis or HAART. 
• Neonatal HIV HIV-PCR test results  During the 3 years that the data reflects, the PMTCT protocol was changed in March 2013 from World Health Organisation (WHO) Option A, to Option B. [5] The major difference involved a switch from prophylaxis for women with a CD4 count >350 to HAART for all HIV+ pregnant or breastfeeding women regardless of CD4 count. (Table 
2.1)               
OPTION/YEAR MATERNAL LABOUR AND DELIVERY NEONATES 
A: 
2010 – 2013* 
CD4 ≤ 350, stage 3 or 4 HIV, TB/HIV co-infection:   
HAART (TDF +3TC/FTC + NVP)  
 
∗ Continue HAART • 6 weeks of NVP 
• 6 week HIV-PCR  test 
• Breastfeeding encouraged BUT free formula provided for 6 
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Table 2.1: PMTCT regimens during time of study (2012 - 2014) 
 
HAART = Highly active antiretroviral therapy, TDF = Tenofovir, 3TC = Lamivudine, FTC = Emtricitabine, NVP = Nevirapine, HIV = Human 
Immunodeficiency Virus, TB = Tuberculosis, HIV-PCR  = Polymerase Chain Reaction, AZT = Zidovudine, sd = single dose 
• National PMTCT guidelines[6]  
• ** Western Cape PMTCT guidelines[7]  A database of this information was collected in a Microsoft Excel spread sheet. Ethical approval for this study was obtained from the UCT Faculty of Health Sciences Research Ethics committee (HREC603/2015).  
ANALYSES Continuous variables i.e. birth weight, gestational age and length-of-stay were assessed for normal distribution by testing for normality using the Shapiro-Wilk test online calculator at http://contchart.com/goodness-of-fit.aspx.  Only the data for the HIV-PCR + babies tested as being normally distributed.  However,  given the small sample size, which predisposes to testing positive for normal distribution, the lack of correlation on visual inspection of histogram analysis (using StatPlus:mac, Analystsoft Inc.) and because the comparative group of HIV-PCR - babies were not normally distributed, non-parametric testing was used to test all continuous variables including the HIV-PCR +/HIV-PCR - data. A comparison of medians was done using the Vassarstats online Mann-Whitney U test calculator available at http://www.vassarstats.net/utest.html.  Univariate analysis of categorical variables was done using Medcalc online statistical software (https://www.medcalc.org/calc/) using  Chi-square and Pearson tests as well 
CD4 > 350:  
AZT from 14 weeks gestation • sdNVP at onset of labour • 3 hourly AZT during labour • sdTDF +FDC post-delivery 
months if formula feeding chosen. 
B: 
2013 – 2015** 
All pregnant and breastfeeding women eligible for HAART If on HAART – continue.  If no antenatal HAART 
• sdNVP at onset of labour 
• 3 hourly AZT during labour 
• Evaluate post delivery for HAART 
If ≥ 8 weeks of maternal HAART:  
4 weeks of NVP 
If < 8 weeks of maternal HAART:  
12 weeks of NVP 
Birth HIV-PCR  based on discretion of attending doctor based on clinical suspicion OR high risk neonate.  
All babies = 6 week HIV-PCR  testing 
Feeding as above 
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as Fisher-exact tests to determine odds ratios and p-value significance. We used two-tail p-values and a α-value of 0.05 to determine significance.  Analysis was done in three categories: i. HIV-exposed vs. HIV-unexposed neonates ii. Neonates with adequate maternal ARV exposure vs. maternal ARV-underexposed neonates iii. HIV-PCR  positive vs. HIV-PCR  negative neonates    
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3. RESULTS  Between January 2012 and December 2014, 1593 VLBW neonates were admitted to the neonatal unit.  Of these, 14 had no HIV exposure status documented and were subsequently excluded. Of the remaining 1579, 316 (20%) were HIV-exposed and 1263 (79%) were unexposed.  
Figure 3.1.1: Distribution of the cohort based on HIV-exposure status 
 The ethnicity of the study population is broken down in Table 3.1.1. African babies made up the largest proportion of the cohort (58%), followed by Coloured (41%). 1% of the cohort was attributed to 11 White babies and 4 who were Asian.       
HIVE = HIV exposed, HIVU = HIV unexposed    
Jan 2012 - Dec 2012 1593 admissions
HIV exposure unknown = 14 1579 neonates
HIV exposed 316
PCR + 11PCR unknown 86 PCR - 219
HIV unexposed 1263
Table 3.1.1: Ethnicity of cohort by HIV status 
Ethnicity 
n (%) 
HIVE (%) 
n = 316 
HIVU 
n = 1263 
Black  
n = 919 (58) 
272 (30) 647 (70) 
Coloured 
n = 646 (41) 
42 (6) 604 (94) 
White 
n = 11 ( 0.7) 
0  11 (100) 
Asian  
n = 4 ( 0.3) 
3 (75) 1 (25) 
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3.1 HIV EXPOSED VS HIV UNEXPOSED NEONATES 
MATERNAL CHARACTERISTICS.   There was no significant difference between any of the maternal variables with regards to HIV exposure although there was a trend to less chorioamnionitis in the HIVE neonates.  These are summarized in table 3.1.2. 
 
 
 
HIVE = HIV-exposed, HIVU = HIV-unexposed, OR = odds ratio, CI = 95% confidence interval, ANC = antenatal 
care, HT = hypertension, NVD = normal vaginal delivery  
NEONATAL CHARACTERISTICS  As depicted in the figures 3.1.2-3.1.4, there was no difference in the median birth weight, gestational age or length-of-stay between the HIVE and HIVU groups. Median birth weight was 1120g for both groups (p = 0.83), median gestational ages 30 weeks for both groups (p = 0.54) and median length of stay 34 days and 37 days (p = 0.16).   
 
 
 
 
 
 
HIVE = HIV-exposed, HIVU = HIV-unexposed, IQR = interquartile range 
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p = 0.83
 HIVE   
n 316(%) 
HIVU        
n 1263(%) 
p value OR (CI) 
ANC 267 (85) 1053 (83) 0.63 1.1 (0.77 -1.5) 
CHORIOAMNIONITIS 8 (3) 65 (5) 0.051 0.48 (0.23 -1.0) 
HT 156 (49) 585 (46) 0.33 1.1 (0.88-1.45) 
ANTENATAL 
STEROIDS 
203 (64) 778 (62) 0.39 1.12 (0.87-1.45) 
NVD 103 (33) 433 (34) 0.57 0.93 (0.71-1.21) 
Table 3.1.2: Maternal characteristics for HIVE and HIVU neonates.  
Figure 3.1.2: Box plot distribution for birth weight of HIVE vs. HIVU 
  
MEDIAN 1120g 1120g 
IQR 910g – 1305g 930g – 1300g 
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HIVE = HIV-exposed, HIVU = HIV-unexposed, IQR = interquartile range    
  
 
 
 
HIVE = HIV-exposed, HIVU = HIV-unexposed, IQR = interquartile range 
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Figure 3.1.3: Box plot distribution for gestational age of HIVE and HIVU neonates.  
            
      
MEDIAN 30 WEEKS 30WEEKS 
IQR 28 -32 28 -32 
Figure 3.1.4: Box plot distribution for length-of-stay for HIVE and HIVU neonates 
MEDIAN 34 days 37 days 
IQR 20 - 48 23 - 51 
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The remaining neonatal outcomes are summarised in Table 3.1.3. 
Table 3.1.3: Neonatal outcomes of HIVE and HIVU infants 
 
HIVEU = HIV-exposed but uninfected, HIVU = HIV-unexposed, OR = odds ratio, CI = 95% confidence interval, SGA = 
small for gestational age, NIV = non-invasive ventilation, NPO2 = nasal cannula oxygen, CLD =  chronic lung disease, 
NEC = necrotising enterocolitis, IVH = Intraventricular haemorrhage, PVL = periventricular leukomalacia 
 
   
OUTCOME HIVE                           
n = 316 (%) 
HIVU                
n = 1263 (%) 
p 
VALUE 
OR (CI) 
 MALE 148 (47) 591 (47) 0.99  
 SGA 170 (54) 668 (53) 0.77 1.04 (0.81-1.3) 
 DEATH 73 (23) 242 (19) 0.12 1.27 (0.94-1.71) 
Delivery 
Room 
Resuscitation 
FACEMASK VENTILATION 167 (53) 678 (54) 0.8 0.76 (0.76 – 1.24) CHEST COMPRESSIONS 39 (12) 196 (15) 0.16 0.77 (0.53-1.12) INTUBATION 29 (9) 117 (9) 0.96 0.99 (0.65 – 1.52) DRUGS 12 (4) 34 (3) 0.3 1.43 (0.73-2.79) 
Respiratory 
Support 
VENTILATION 83 (26) 264 (21) 0.04 1.35 (1.01 – 1.8) NIV 255 (81) 992 (78) 0.4 1.14 (0.84 -1.56) NPO2 268 (85) 1052 (84) 0.51 1.12 (0.8 – 1.57) SURFACTANT 94 (30) 384 (30) 0.82 0.97 (0.74 – 1.27) CLD 17 (5) 53 (4) 0.36 1.3 (0.74 -2.27) 
Sepsis EARLY SEPSIS 6 (2) 20 (2) 0.69 1.2 (0.48 - 3.02) LATE SEPSIS 31 (10) 103 (8) 0.35 1.23 (0.8 -1.87) NOSOCOMIAL 32 (10) 113 (9) 0.51 1.15 (0.76 – 1.74) FUNGAL 1 (0.3) 7 (2) 0.6 0.57 (0.07 – 4.65) 
NEC NEC 34 (11) 78 (6) 0.005 1.83 (1.2 – 2.8) NEC SURGERY 5/34 (22) 16/78 (20) 0.47 0.67 (0.22 – 2.0) NEC DEATH 21/34 (62)  41/78 (53) 0.37 1.46 (0.64 – 3.3) 
 ANY SURGERY 13 (4) 37 (3) 0.28 1.42 (0.75 – 2.71) 
Neurological ANY IVH 68/275 (25) 316/1088 (29) 0.16 0.8 (0.59 – 1.1) HIGH GRADE IVH  (grade III or IV) 
 
20/275 (7) 57/1088 (5) 0.19 1.4 (0.84 -2.4) 
PVL 6/275 (2) 26/1088 (2) 0.84 0.91 (0.37 – 2.24) 
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i. VENTILATION  HIVE neonates were ventilated more often (OR 1.35, CI 1.01 -1.8, p=0.04).  As summarized in Table 3.1.4, within this subgroup of HIVE and HIVU neonates, there was no difference between factors that may have predisposed to a need for ventilation. These included SGA, maternal ANC, chorioamnionitis, antenatal steroids, type of delivery, administration of surfactant, sepsis or incidence of NEC. There was also no difference in median birth weight (both 1100 grams, p =0.65) or median gestational age (30 weeks and 29 weeks respectively, p=0.19).  
Table 3.1.4: Sub-group analysis of HIVE and HIVU neonates who required ventilation 
 
HIVE = HIV-exposed, HIVU = HIV-unexposed, IQR = interquartile range, SGA = small for gestational age, ANC = 
antenatal care, NVD = normal vertex delivery, NEC = necrotising enterocolitis,   ii. NEC  More HIVE neonates were diagnosed with NEC (OR 1.83, CI 1.2 – 2.8, p=0.005), however of those who developed NEC, there was no difference in outcome with regards to surgery (p=0.47) or death (p = 0.37, Table 3.1.3). Sub-group analysis of SGA, maternal ANC, antenatal steroids, and gestational age revealed no difference between the groups but a significant difference in birth weight was noted. HIVE babies, with a median birth weight of 898g compared to 1118g in the HIVU group, weighed less (p=0.008). Table 
3.1.5, Figure 3.1.5. 
 
  
 HIVE 
n=83 (%) 
HIVU 
n=264 (%) 
p VALUE 
MEDIAN BIRTH WEIGHT  1100g IQR (930 -1278g) 1100g IQR (960g – 1240g) 0.65 
MEDIAN GESTATIONAL AGE 30 weeks IQR (28 – 31) 29 weeks IQR (28 – 31) 0.19 
SGA 34 (41) 88 (33) 0.21 
ANC 71 (86) 205 (78) 0.12 
CHORIOAMNIONITIS 6 (8) 14/254 (6) 0.57 
ANTENATAL STEROIDS 39 (47) 119 (45) 0.76 
NVD 29 (35) 107 (41) 0.36 
NEC  15 (18) 43 (16) 0.7 
EARLY SEPSIS 4 (5) 12 (5) 0.92 
LATE SEPSIS 11 (13) 51 (20) 0.21 
SURFACTANT 59 (71) 204 (77) 0.25 
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HIVE = 
HIV-
exposed, HIVU = HIV-unexposed, SGA = small for gestational age, ANC = antenatal care   
 
 
 
 
 
HIVE = HIV-exposed, HIVU = HIV-unexposed, IQR = interquartile range, NEC = necrotising enterocolitis         
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p = 0.008
 HIVE 
n = 34 (%) 
HIVU 
n = 78 (%) 
p VALUE 
MEDIAN BIRTH WEIGHT FIGURE 3.1.5 
MEDIAN GESTATIONAL AGE 29 weeks IQR (28 – 30) 29 weeks IQR (28 -31) 0.57 
SGA 18 (60) 35 (45) 0.16 
ANC 23 (77) 65 (84) 0.35 
ANTENATAL STEROIDS 19 (63) 45 (58) 0.59 
Table 3.1.5: Sub-group analysis of HIVE and HIVU neonates who developed NEC. 
Figure 3.1.5: Box plot distribution of birth weights for HIVE vs. HIVU neonates who developed NEC 
MEDIAN 898g 1118g 
IQR 833g – 1100g 896g – 1244g 
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FEEDING AT DISCHARGE  Feeding at discharge was documented for 178 (56%) of the HIVE and 721 (57%) of the HIVU neonates. In both groups, the majority of the babies (49% and 76% respectively) were discharged on exclusive breastfeeding. (Table 3.1.6) Less HIVE babies were discharged on EBM (0.3, CI 0.22 – 0.43, p  <0.0001) and mixed feeding (OR 0.56, CI 0.33 – 0.93, p = 0.026) compared to HIVU babies. More HIVE infants were however discharged on exclusive formula feeding (OR 9.97, CI 6.5 – 15.2, p = <0.0001).         
HIVE = HIV-exposed, HIVU = HIV-unexposed, OR = odds ratio, CI = 95% confidence interval, EBM = exclusive 
breast milk    
Table 3.1.6: Feeding at discharge for HIVE and HIVU neonates.  
 HIVE 
n =178 (%) HIVU n = 721 (%) p-value OR (CI) 
EBM 87 (49) 547 (76) <0.0001 0.3 (0.22 – 0.43) 
FORMULA 72 (40) 46 (6) <0.0001 9.97 (6.5 – 15.2) 
MIXED 19 (11) 127 (18) 0.026 0.56 (0.33 – 0.93) 
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3.2 MATERNAL ARV-EXPOSED VS. MATERNAL ARV UNDER-EXPOSED  Adequate maternal ARV-exposure (mARVE) was defined as those mothers who were documented as having antenatal exposure to ARV’s for ≥ 8 weeks at the time of delivery, or had a documented suppressed viral load at the time of delivery when ARV-exposure was uncertain.  The maternal ARV under-exposed (mARVU) group included those babies whose mothers had less than 8 weeks, or no exposure to ARV’s prior to delivery.  Of the 316 HIV-positive mothers, 58% were exposed to adequate ARV’s and 31% were classified as ARV under-exposed. Within these 99 mothers, 36 received no ARV’s, and 63 received <8 weeks of ARV’s. The remaining 11% had incomplete records. These 34 infants were subsequently excluded from this analysis.  (Figure 3.2.1) 
Figure 3.2.1: Distribution of maternal antiretroviral (ARV) exposure among the HIV-exposed cohort 
 
                 
HIV EXPOSED NEONATES n=316
Maternal ARV exposed n=183 
(58%)
Maternal ARV under-exposed n=99 (31%)
No Maternal ARV's n = 36 < 8 weeks Maternal ARV's n = 63
ARV exposure unknown n=34
(11%)
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MATERNAL CHARACTERISTICS  Adequate maternal ARV exposure was associated with more ANC (OR 3.0, CI 1.5 – 6.0, p=0.002), but no other difference was noted. (Table 3.2.1)   
 
ARV = antiretroviral, mARVE = maternal ARV exposed, mARVU = maternal ARV under-exposed, OR = odds ratio, 
CI = 95% confidence interval, ANC = antenatal care 
 
NEONATAL CHARACHTERISTICS  There was no significant difference in gestational age, birth weight and length-of-stay for mARVE and mARVU neonates. Median gestational ages for both groups were 30 weeks (p = 0.24, figure 3.2.2) and birth weight medians were 1140g and 1100g respectively (p = 0.52, figure 3.2.3). There was a trend towards a longer admission in the mARVU group with a median length-of-stay of 38 days in comparison with the mARVE group’s 30 days (p=0.054, figure 3.2.4).           
Table 3.2.1: Maternal characteristics of mARVE and mARVU neonates.  
 mARVE             
n = 183 (%) mARVU                n = 99 (%)  p-value OR (CI) 
ANC 167 (91) 77 (77) 0.002 3.0 (1.5 – 6.0) CHORIOAMNIONITIS 4 (2) 4 (4) 0.37 0.53 (0.13 – 2.1) HYPERTENSION 96 (52) 45 (45) 0.26 1.3 (0.81 – 2.2) ANTENATAL STEROIDS 125 (68) 58 (58) 0.1 1.45(0.92 – 2.53) VAGINAL DELIVERY 52 (28) 36 (36) 0.17 0.69 (0.4 – 1.17) 
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ARV = antiretroviral, mARVE =maternal ARV-exposed, mARVU = maternal ARV under-exposed, IQR = 
interquartile range        
    
ARV = antiretroviral, mARVE = maternal ARV-exposed, mARVU = maternal ARV under-exposed, IQR = 
interquartile range    
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Figure 3.2.2: Box plot distribution of gestational ages for mARVE and mARVU neonates 
MEDIAN 30 weeks 30 weeks 
IQR 28 -32 weeks 29 – 32 weeks 
Figure 3.2.3: Box plot distribution of birth weight for mARVE and mARVU neonates.  
MEDIAN 1140g 1100g 
IQR 890g – 1350g 943g -1288g 
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ARV = 
antiretroviral, mARVE = ARV-exposed, mARVU = ARV-unexposed, IQR = interquartile range                  
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Figure 3.2.4: Box plot distribution of length-of-stay for mARVE  and mARVU neonates.  
MEDIAN 30 days 38 days 
IQR 20 – 46 days 20 -53 days 
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Table 3.2.2: Neonatal outcomes for mARVE and mARVU infants  
 
 
ARV = antiretroviral, mARVE = maternal ARV exposed, mARVU = maternal ARV under-exposed, OR = odds ratio, 
CI = 95% confidence interval, SGA = small for gestational age, NIV = non-invasive ventilation, NPO2 = nasal 
cannula oxygen, CLD = chronic lung disease, NEC = necrotising enterocolitis, IVH = Intraventricular 
haemorrhage, PVL = periventricular leukomalacia  The remaining neonatal outcomes are summarized in table 3.2.2. A trend to less need for invasive ventilation was seen in the mARVE group (p=0.051).  The incidence of NEC was again significant. Adequate maternal ARV’s were associated with less NEC in the neonates compared to mARVU neonates (OR 0.4, CI 0.18 – 0.86, p = 0.02). In the mARVE neonates who developed NEC however, mortality was significantly higher (OR 12, CI 1.9 – 76, p = 0.008).  
OUTCOMES mARVE      
n = 183 (%) mARVU       n = 99 (%) p-value OR (CI)  MALE 76 (42) 54 (55) 0.037   SGA 101 (55) 51 (51) 0.55 1.2  (0.71 – 1.9)  DEATH 41 (22) 25 (25) 0.6 0.85 (0.48 – 1.5) 
Delivery 
Room 
outcomes 
FACE MASK VENTILATION 102 (56)  55 (56) 0.98  1 (0.62 – 1.65) CHEST COMPRESSIONS 24 (13) 12 (12) 0.81  1.1 (0.52 – 2.3) INTUBATION 17 (9) 10 (10) 0.83 0.9 (0.4 – 2.1) DRUGS 8 (4) 3 (3) 0.58 1.46 (0.4 – 5.6) 
Respiratory 
outcomes 
VENTILATION 38 (21) 31 (31) 0.051 0.57 (0.33 – 1.0) NIV 141 (77) 85 (86) 0.08 0.55 (0.3 – 1.1) NPO2 154 (84) 85 (86) 0.7 0.87 (0.4 – 1.74) SURFACTANT 49 (27) 29 (29) 0.65 0.88 (0.5 – 1.52) CLD 9 (5) 6 (6) 0.68  0.8 (0.3 – 2.3) 
Sepsis EARLY SEPSIS 2 (1) 4 (4) 0.13  0.26 (0.05 – 1.46) LATE SEPSIS 15 (8) 15 (15) 0.07 0.5 (0.23 – 1.1) NOSOCOMIAL 15 (8) 15 (15) 0.07 0.5 (0.23 – 1.1) FUNGAL 0 0 0.76 0.54 (0.01 – 27.3) 
NEC NEC 13 (7) 16 (16) 0.02 0.4 (0.18 – 0.86) NEC SURGERY 3/13 (23) 2/16 (13) 0.46  2.1 (0.3 – 15) 
NEC DEATH 11/13 (85) 5/16 (31) 0.008 12 (1.9 – 76)  ANY SURGERY 8 (4) 5 (5) 0.8  0.86 (0.27 – 2.7) 
Neurological ALL IVH 34/160 (21) 26/84 (26) 0.096 0.6 (0.3 – 1.09) HIGH GRADE IVH  (Grade 3 or 4) 10/160 (6) 7/84 (7) 0.55 0.73  (0.27 – 2.00) PVL 4 /160(2) 1/84 (1) 0.5 2.1 (0.23 – 19) 
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Sub-group analysis of the mARVE NEC cohort (Table 3.2.3) showed no difference in ANC (p = 0.06), antenatal steroids (p = 0.96), gender (p =0.54) or gestational age (p = 0.11), however birth weight was again significantly different between the mARVE and mARVU groups. Birth weight was significantly less among mARVE neonates compared to the mARVU neonates who contracted NEC (p=0.024). Figure 3.2.5 
Table 3.2.3: Sub-group analysis of mARVE and mARVU neonates who developed NEC 
 mARVE 
n = 13 (%) mARVU n = 16 (%) p-value 
MEDIAN GESTATIONAL 
AGE 28 weeks IQR 27 – 30 weeks 30 weeks IQR 29 – 31 weeks 0.11 
MALE 5 (38) 8 (50) 0.54 
SGA 6 (46) 9 (56) 0.47 
ANC 13 (100) 10 (63) 0.06 
ANTENATAL STEROIDS 8 (62) 10 (62) 0.96 
 
ARV = antiretroviral, mARVE =maternal ARV-exposed, mARVU = maternal ARV under-exposed, SGA = small for 
gestational age, ANC = antenatal care    
 
 
 
 
 
ARV = antiretroviral, mARVE = maternal ARV-exposed, mARVU = maternal ARV under-exposed, NEC = 
necrotising enterocolitis 
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Figure 3.2.5: Box plot distribution of birth weight of mARVE and mARVU neonates who developed 
NEC  
 
MEDIAN 850g 1090g 
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RANGE 
830 – 915g 850 -1265g 
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3.3 HIV-PCR POSITIVE VS. HIV-PCR NEGATIVE NEONATES  As shown in Figure 3.3.1, of the 316 HIVE babies, 86 had no retrievable HIV-PCR test result. Eleven out of 230 HIV-PCR tested neonates were HIV-PCR positive (4.8%) and 219 were HIV-PCR negative (95.2%). Fifty-three out of the 230 (23%) who had documented testing, had early HIV-PCR testing i.e. prior to 6 weeks. All 11 HIV-PCR positive infants were from this early testing group.  Most of this testing was done in the first week of life, (median day of testing = day 1 of life, IQR 1 -5 days). Only 2 early HIV-PCR tests were done in 2012, 11 were done in 2013 and the remaining 40 were done in 2014. Among the 177 neonates who had a HIV-PCR test done at or after 6 weeks, all tests were negative. Of the 86 untested neonates, 52 (60%) died in the first 6 weeks of life and most of these were in the first 2 weeks (median LOS 4 days, IQR 3 – 11 days). Thirty of the 34 neonates with no retrievable HIV-PCR test were discharged prior to 6 weeks of age and 4 were discharged after. (Figure 3.3.2)   
Figure 3.3.1: Distribution of HIVE neonates based on HIV-PCR -testing and HIV-PCR -status   
 
HIV EXPOSED n = 316
PCR not documented n = 86 PCR tested     n = 230
early PCR testing n = 53
11 PCR-POSITIVE 42 PCR-NEGATIVE
6 weeks or older testing n = 177
177 PCR-NEGATIVE
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Figure 3.3.2: Flowchart representation of infant disposition and timing of HIV-PCR testing 
   
316 HIVE neonates
230 PCR tested (73%)
53 Early PCR test (23%)
11 PCR positive
177 > 6 week test (77%)
86 PCR not tested (27%)
52 died < 6 weeks (60%) 34 discharged (40%)
30 < 6weeks so ? different name/ died/ relocated 4  discharged > 6 weeks
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MATERNAL CHARACTERISTICS  The only statistically different maternal characteristic between the HIV-PCR positive neonates and HIV-PCR negative was related to maternal ARV exposure. HIV-PCR positive neonates were significantly less likely to have a mother on ARV’s for >2 months at the time of delivery (OR 0.12, CI 0.02 – 0.58, p = 0.008). Table 3.3.1 
Table 3.3.1: Maternal Characteristics of HIV-PCR positive and HIV-PCR negative neonates.  
 HIV-PCR + 
n = 11 (%) HIV-PCR - n = 219 (%) p-value OR (CI) ANC 8 (72) 182 (83) 0.27 0.46 (0.12 – 1.81) CHORIOAMNIONITIS 0 5 (2) 0.8 1.5 (0.08 – 26.7) HYPERTENSION 5 (45) 102 (47) 0.82 0.9 (0.26 – 2.9) ANTENATAL STEROIDS 5 (45) 147 (67) 0.21 0.46 (0.14 – 1.54) VAGINAL DELIVERY 6 (54) 67 (31) 0.13 2.5 (0.75 – 8.5) 
mARVE 2/10 (20) 133/196 (68) 0.008 0.12 (0.02 – 
0.58) 
 
HIV-PCR = polymerase chain reaction, HIV-PCR + = HIV-PCR -positive, HIV-PCR - = HIV-PCR -negative, OR = 
odds ratio, CI = 95% confidence interval, ANC = antenatal care, mARVE = >2 months of maternal antiretroviral 
exposure. 
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NEONATAL CHARACTERISTICS  There was no difference between the median gestational ages of the two groups (Figure 
3.3.3, p = 0.38), birth weight (Figure 3.3.4, p = 0.61) or length-of-stay (Figure 3.3.5, p = 0.41).  
     
HIV-PCR = polymerase chain reaction, HIV-PCR + = HIV-PCR  positive, HIV-PCR - =negative, IQR = interquartile 
range 
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Figure 3.3.3: Box plot distribution of gestational age for HIV-PCR positive and HIV-PCR negative 
neonates. 
Median 30 weeks 30 weeks 
IQR 29 – 33 weeks 29 – 32 weeks 
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Figure 3.3.4: Box plot distribution for birth weights of HIV-PCR positive and HIV-PCR -negative 
neonates  
 
 
 
 
 
 
HIV-PCR = polymerase chain reaction, HIV-PCR + = HIV-PCR  positive, HIV-PCR - = HIV-PCR  negative, IQR =  
interquartile range 
  
 
HIV-PCR = polymerase chain reaction, HIV-PCR + = HIV-PCR  positive, HIV-PCR - = HIV-PCR  negative, IQR = 
interquartile range   
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MEDIAN 1230g           1150g 
IQR 1090g – 1250g      960g – 1330g 
MEDIAN 46 days 39 days 
IQR 34 – 58 days 27 – 52 days 
Figure 3.3.5: Box plot distribution for length-of-stay of  HIV-PCR positive and HIV-PCR  negative 
neonates. 
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Of the remaining neonatal outcomes (Table 3.3.2), differences emerged regarding non-invasive ventilation, CLD and NEC.    
 
HIV-PCR  = polymerase chain reaction, HIV-PCR + = HIV-PCR  positive, HIV-PCR - = HIV-PCR  negative, OR = odds 
ratio, CI = 95% confidence  
interval SGA = small for gestational age, NIV = non-invasive ventilation, NPO2 = nasal cannula oxygen, CLD = 
chronic lung disease, NEC = necrotising enterocolitis, IVH = Intraventricular haemorrhage, PVL = periventricular 
leukomalacia.    
Table 3.3.2: Neonatal outcomes of HIV-PCR positive and HIV-PCR negative neonates.  
OUTCOMES HIV-PCR + n=11 HIV-PCR -      n=219 p Value OR (CI)  MALE 6 (55) 97 (44) 0.47   SGA 7 (63) 115 (53) 0.4 1.72 (0.49-6.04)  DEATH 2 (18) 22 (10) 0.40 1.99 (0.40-9.80) 
Delivery 
Room 
outcomes 
FACE MASK VENTILATION 7 (64) 106 (48) 0.33 1.87 (0.53-6.56) CHEST COMPRESSIONS 1 (9) 22 (10) 0.92 0.90 (0.11-7.33) INTUBATION 1 (9) 18 (8) 0.92  1.12 (0.14-9.22) DRUGS 0 5 (2) 0.73 1.70 (0.09-32.57) 
Respiratory 
support 
VENTILATION 2 (18) 52 (24) 0.67 0.71 (0.15-3.41) 
NIV 6 (55) 177 (81) 0.046 0.28 (0.08-0.98) NPO2 8 (72) 184 (84) 0.33 0.51 (0.13-2.01) SURFACTANT 1 (9) 65 (30) 0.17 0.24 (0.03-1.89) 
CLD 3 (27) 14 (6) 0.02 5.49 (1.31-23.02) 
Sepsis EARLY SEPSIS 1 (9) 2 (1) 0.06 10.8 (0.91-129.92) LATE SEPSIS 0 21 (10) 0.53 0.4 (0.02-7.05) NOSOCOMIAL 0 22 (10) 0.51 0.38 (0.02–6.7) FUNGAL 0 1 (0.5) 0.27 6.3 (0.24-164.18) 
NEC NEC 3 (27) 18 (8) 0.047 4.12 (1.02-17.18) NEC SURGERY 0/3 4/18(22) 0.63 0.46 (0.02-10.70) NEC DEATH 1/3(33) 8 /18(44) 0.72 0.63 (0.05-8.20)  ANY SURGERY 0 12 (5) 0.83  0.72 (0.04-12.97) 
Neurological 
10 HIV-PCR + 
203 HIV-PCR - 
ANY IVH 2 (20) 46 (23) 0.84 0.85 (0.18-4.16) HIGH GRADE IVH (grade III and IV) 0 14 (7) 0.75 0.62 (0.03-11.2) PVL 0 5 (2) 0.72 1.72 (0.09-33.20) 
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i. Non-invasive ventilation   55% of the HIV-PCR -positive neonates required non-invasive ventilation, which was significantly less than the 81% of the HIV-PCR negative neonates (OR 0.28, CI 0.08 – 0.98, p = 0.046). There was no difference when correcting for median birth weights (p = 0.165), gestational ages (p = 0.165), SGA (p = 0.37), antenatal steroids (p = 0.55), antenatal care (p = 0.07) or surfactant use (p = 0.35). (Table 3.3.3)  
Table 3.3.3: Subgroup analysis of HIV-PCR positive and HIV-PCR negative neonates who required 
non-invasive ventilation.  
 HIV-PCR + 
n = 6 (%) HIV-PCR - n = 177 (%) p-value 
MEDIAN BIRTH WEIGHT 1090grams IQR (979 – 1160) 1100grams IQR (910 – 1270) 0.165 
MEDIAN GESTATIONAL AGE 30 weeks IQR (29 – 32wks) 30 weeks IQR (29 – 32wks) 0.165 
SGA 4 (67) 84 (47) 0.37 
ANC 3 (50) 145 (82) 0.07 
ANTENATAL STEROIDS 3 (50) 110 (62) 0.55 
VAGINAL DELIVERY 2 (33) 60 (34) 0.49 
SURFACTANT 1 (17) 64 (36) 0.35 
 
HIV-PCR = polymerase chain reaction, HIV-PCR + = HIV-PCR positive, HIV-PCR - = HIV-PCR  negative, SGA = 
small for gestational age, ANC = antenatal care, IQR = interquartile range  ii. Chronic Lung Disease  Despite needing less non-invasive ventilation, significantly more HIV-PCR positive babies developed CLD compared to the HIV-PCR negative babies (OR 5.49, CI 1.31 – 23, p = 0.02). (Table 3.3.2) iii. NEC HIV-PCR positive babies had an increased risk of developing NEC (OR 4.12, CI 1.02 – 17.18; p=0.047). (Table 3.3.2) Sub-group analysis was not carried out on these two variables as the numbers affected were considered too small to yield any statistically reliable results.   
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4. DISCUSSION  Worldwide, as care of HIV mothers has improved and effective PMTCT regimens have been implemented, drastically reduced perinatal transmission of HIV has resulted in the unmasking of a vulnerable population of infants and children who are HIV exposed yet uninfected. A growing body of literature is finding these children to be at increased risk of infections and death despite the absence of HIV. The mechanism is likely multifactorial and some proposed aetiologies include an innate immunodeficiency driven by antenatal exposure to ARV’s, in-utero exposure to HIV viral particles or impaired maternal immune function. Additionally these children are at risk of nutritional deficiencies due to suboptimal breastfeeding practices and lower socioeconomic status often associated with HIV exposed households. [8] HIV exposed pregnancies have also been associated with more premature and LBW birth outcomes then HIV unexposed pregnancies. [9] This may be directly linked to poor maternal health and indirectly related to HIV associated socioeconomic factors or in-utero exposure to maternal ART. The literature to date about premature HIVE neonates is limited by the small numbers of neonates who survive prematurity in resource-poor yet high HIV prevalence areas such as Sub-Saharan Africa. Consequently, many clinicians have a perception that HIVE neonates are often premature, smaller and sicker, with increased mortality. The Groote Schuur unit is well placed for this research as it is situated in a high prevalence HIV area that is able to provide NCPAP and surfactant therapy to these VLBW neonates which improves their survival. [1,10] This study provides the first piece of literature that examines a cohort of HIVE, premature and VLBW neonates with a comparative cohort of HIVU neonates. It is the first to report on several comparative short-term neonatal outcomes in HIVE, antenatal ARV-exposed and HIV-PCR positive VLBW neonates. These include birth weight, gestational age, SGA, length-of-stay, IVH, respiratory and delivery room resuscitation outcomes. The data on NEC is also the first to report on outcomes related to antenatal ARV-exposure and infant HIV-PCR status.  
HIV-EXPOSED VERSUS HIV-UNEXPOSED NEONATES  There was no difference in maternal characteristics that may have influenced outcomes in these neonates including antenatal care exposure to antenatal steroids or type of delivery. There was no increased hypertension among HIV-positive mothers compared to HIV-negative mothers, which is consistent with the meta-analysis findings of Brown et al, who showed no increased PIH in relation to maternal HIV[11]. There was a trend towards less chorioamnionitis among the HIV-positive mothers (OR 0.48, CI 0.23 – 1.0, p = 0.051) which is surprising as chorioamnionitis has been shown to be of equal or increased prevalence between HIV positive and HIV negative mothers [12,13]. Due to the small numbers of documented cases however, i.e. 8/316 (3%) in the HIV-positive mothers and 65/1263 (5%) among those who are HIV-negative, the question is whether cases of chorioamnionitis were being properly identified during admission. VON data 
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capturing does not offer specific clinical criteria for chorioamnionitis and at GSH, placentas are not routinely sent off for histological analysis. The validity of this finding is thus questionable.  There was no difference between mortality of HIVE neonates (23%) and HIVU neonates (19%). This correlates with most of the current literature on neonatal mortality that has been compared between HIVE and HIVU neonates in 5 previous studies [14-18]. Two of these studies focused on premature and LBW infants and both reported no difference in mortality. The first, a small South African based cohort of 70 neonates, found no difference in mortality between HIVE and HIVU neonates[18]. The second study from Botswana, with a cohort of 449 neonates and a median gestational age of 34 weeks, also showed no significant difference between the 27% of the HIVE neonates who died compared to 20% of the HIVU neonates (p = 0.19) [14].  There was no difference between HIVE and HIVU neonates with regards to median birth weight, gestational age and length-of-stay. This differs from the meta-analysis findings published by Xiao et al in 2015 which showed both an increased risk of LBW (pooled OR 1.73, CI 1.64 – 1.82) and prematurity (pooled OR 1.56, CI 1.49 – 1.63) among HIVE neonates[9]. In previous studies, Parekh et al have found an increased risk for neonates to be very-small-for-gestational-age among HIVE infants in Botswana (aOR 1.9, CI 1.41 – 2.55)  and Sofeu et al from Cameroon have demonstrated less SGA among HIVU neonates compared to HIVEU neonates (aOR 0.5, 95% CI 0.4 – 0.7) [19,20]. There was however no difference in SGA among this cohort of GSH HIVE neonates compared to those who are HIVU. This could be because of better maternal health among the mothers in the Western Cape as compared to Botswana and Cameroon for either socio-economic reasons or as a result of better access to ARV’s. Alternatively, since a large proportion of the deliveries at GSH are related to pregnancy related hypertensive disorders, it could be that HIVU neonates were significantly growth restricted for this reason [21].  The incidence of sepsis among the HIVE neonates is of interest due to the increased risk of sepsis that has recently come to the fore among HIV-exposed but uninfected older infants and children[22,23]. The literature pertinent to neonates has previously been reviewed by Slogrove et al and concluded that the neonatal period is an equally high-risk period for sepsis for both HIVE and HIVU neonates[24]. Most of the literature on neonatal sepsis in HIVE neonates relates to Group B Streptococcus (GBS) and so is difficult to compare to this study data as VON does not keep a record of specific organisms cultured. Only Cutland et al have compared all-cause sepsis morbidity in a large Johannesburg based cohort (n = 4108) of HIVE and HIVU neonates[25]. They demonstrated a marginally increased risk of culture positive early onset sepsis among HIVE neonates and no difference in late onset sepsis. The findings in our GSH study demonstrate no significant difference between risk of either early onset sepsis or late onset sepsis. Previous studies from GSH have demonstrated that most of the neonates are delivered by caesarean section for complications related to maternal hypertension [2,21]. This iatrogenic delivery, in the absence of active labour suggests that less GSH neonatal admissions are at risk of septic exposure perinatally. This may underlie the observation of an equal incidence of early onset sepsis.  
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Significant differences that occurred between HIVE and HIVU neonates included need for ventilation and increased risk of NEC. The literature available on respiratory morbidity in HIVE neonates is limited to 2 reports on largely term and normal birth weight infants. Kreitchmann et al reported a morbidity of 7.5% and mostly related to TTN and RDS but with no comparative cohort [26]. Martin et al found no difference in respiratory outcomes compared to general population data [27]. Multiple mechanisms have been postulated to impact on lung growth and function of HIVE neonates, including in-utero exposure to a pro-inflammatory environment, HIV viral particles and maternal co-infections [28].  This study demonstrated 35% more invasive ventilation among HIVE compared to HIVU neonates (OR 1.35, CI 1.01 – 1.8, p = 0.04), and on secondary analysis no clear association with potential confounders could be identified (Table 3.1.4). These included birth weight, gestational age,  and antenatal steroids. Since there was no difference in administration of surfactant it can be assumed that the increased need for ventilatory support was not related to lung immaturity or HMD. This data is limited in that it does not reflect when during admission, for what reason or for how long the baby was ventilated. There was however no difference in NEC, early onset sepsis or late onset sepsis between HIVE and HIVU neonates to suggest a possible reason for ventilation.  NEC outcomes are divided into incidence, clinical presentation and mortality. Almost twice as much NEC was demonstrated among HIVE compared to HIVU babies (OR 1.83, CI 1.2 – 2.8, p = 0.005).  This is consistent with the findings of Desfrere et al who also demonstrated an increased risk in their 2005 case-control cohort of 237 infants in France (OR 6.63, 95% CI 1.26 – 35) [29]. There is only one other study on NEC incidence in HIVE babies and from that Johannesburg based cohort of 330 babies, HIV exposure was not an associated risk factor [30].   Two studies have previously demonstrated an increased mortality among HIVE neonates who developed NEC. Karpelowsky et al demonstrated an almost 5-fold increased mortality (OR 4.8, 95% CI 1.7 – 14.2) and Chokoe et al found an 80% mortality in HIVE infants versus 15% in HIVU (p = 0.0002) [31,32]. However Angura et al and Arnold et al did not demonstrate a difference in mortality among HIVE neonates in their studies[30,33]. Similarly, this GSH study did not demonstrate a difference in mortality in the infants who developed NEC. The incidence of surgery was also no different between the HIVE and HIVU neonates who developed NEC. This correlates with the available literature comparing clinical presentation and histology between HIVE and HIVU neonates that has showed no differences [30,31,33,34]. The pathophysiology of NEC excluding HIV-exposure is poorly understood and is likely related to multiple triggers [35]. Differences in risk factors that are associated with NEC were considered in a secondary analysis of the HIVE neonates who developed NEC (Table 3.1.5). There was no difference in gestational age or antenatal steroid administration  in comparison with the HIVU NEC neonates. There was a significantly lower birth weight in the HIVE neonates who developed NEC compared to the HIVU neonates, with median birth weights of 898g and 1118g respectively (p = 0.008, figure 
3.1.5). Although not a statistically significant proportion, more (60%) of the HIVE 
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neonates who developed NEC were SGA compared to the HIVU neonates (45%, p = 0.16). The lower birth weight and relatively higher proportion of growth restriction is a significant finding with regards to NEC risk in HIVE neonates. The VON database does not include blood transfusion and inpatient feeding records, which limits the interpretation of potential associations for this increased risk of NEC among the HIVE neonates.  Feeding at discharge was documented for half of the cohort (57%). The remainder of the cohort was excluded based on death or transfer. Neonates who died were excluded, as many of them were not fed in the 24 hours prior to death. Neonates who are transferred to a step-down unit for weight gain are almost always still receiving breast milk fortification with FM85, which may skew the analysis in favour of mixed feeding. Within the HIVE cohort the neonates were 10-times more likely to be discharged on formula feeding (OR 9.97, CI 6.5 – 15.2, p = <0.0001), 70% less likely to be discharged on exclusive breast feeds (OR 0.3, CI 0.22 – 0.43, p = <0.0001,) but also 50% less likely to be discharged on mixed feeding (OR 0.56, CI 0.33 – 0.93, p = 0.026). This goes against the current WHO guidelines on infant feeding which recommends exclusive breastfeeding with maternal ART support for PMTCT in developing nations [36]. At the time of our study PMTCT policy encouraged exclusive breastfeeding for the first 6 months. Free infant formula was provided however for mothers who chose to avoid the transmission risk associated with breast milk[6,7]. It is possible that their feeding decision was likely swayed in the direction of formula, based on this incentive. Subsequent to this, the PMTCT policy has been revised in 2015 to withdraw the provision of free formula and increase breastfeeding support in order to promote exclusive breastfeeding of HIVE infants.  
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ADEQUATE MATERNAL ARV-EXPOSURE VS. MATERNAL ARV-UNDER-
EXPOSED NEONATES  The PMTCT regimens in use at the time of our study are discussed in detail in the methods section of this paper and summarised in Table 2.1.  The most recent South African PMTCT guidelines have subsequently been updated in 2015 and have increased the duration of adequate ART exposure from 8 weeks to 12 weeks[37]. Consequently, our decision to use 2 months of ARV-exposure as a cut off for adequate viral suppression in the mothers, may be disputed. There is evidence to encourage 3 months of ART from a UK based study that found HAART initiated after 20 weeks unlikely to reduce viral load to <50 copies/ml by the time of delivery [38]. Aziz et al disputed this however by showing a reduction to <400 copies/ml in a median of 25 days in 2013 and the 2009 Cochrane review had reported there are no RCT’s or observational studies to determine the optimal timing of ARV’s [39,40]. ARVE mothers were 3-times more likely to receive antenatal care compared to those mothers who were ARVU (OR 3.0, CI 1.5 – 6.0, p = 0.002). HIV testing at initial antenatal booking and during pregnancy is an essential component of basic antenatal care in the South African health system. Lack of maternal ART is virtually synonymous with a mother who has not accessed antenatal care. Despite this, there were no other differences in terms of maternal characteristics, including antenatal steroid administration and maternal hypertension. This differs from the finding of a previous study in this unit that demonstrated an association with maternal ART for more than 4 weeks and PIH (p = 0.007) [21]. It is consistent with the findings of Brown et al however in their meta-analysis, which found no association with either HIV or ART and PIH [11]. Although ARVE mothers received more ANC compared to the ARVU mothers, there was no difference in gestational age, birth weight or length-of-stay of the mARVE and mARVU neonates. There was also no difference in SGA proportions or delivery room outcomes. There were less male infants in the mARVE cohort as opposed to mARVU babies. This finding cannot readily be explained but it does not appear to have had any influence on the remaining neonatal outcomes. Similar to the HIVE infants, there was no difference in mortality between mARVE (22%) and mARVU (25%) neonates.  There was a trend among the mARVE neonates for less invasive ventilation compared to the mARVU neonates (OR 0.57, CI 0.33 – 1.0, p = 0.051). This differs from HIVE infants who required more invasive ventilation compared to HIVU neonates (OR 1.35, CI 1.01 – 1.8). In this observation we find that the mARVE neonates demonstrate an outcome that is the same as HIVU neonates (21% required invasive ventilation in mARVE and HIVU groups). This could suggest that adequate maternal ART has a beneficial effect for neonatal lung health indirectly through better maternal health or less exposure to maternal co-infections. The similar use of surfactant between mARVE and mARVU neonates, as in the HIVE and HIVU group, suggests that RDS due to lung immaturity is not the underlying reason for this difference.  
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There was no difference in early onset sepsis between the mARVE and mARVU neonates. Although there was no difference in late onset sepsis, there was a trend of less sepsis in the mARVE cohort (8%) compared to in the mARVU group (15%). Incidentally, the incidence of late onset sepsis in the mARVE neonates is the same as the incidence in HIVU neonates (both 8%). These two observations may suggest a neonatal immune system functionally like HIVU neonates with adequate exposure of maternal ART.  There was a difference in the incidence of NEC with mARVE neonates having 60% less NEC than mARVU neonates (OR 0.4, CI 0.18 – 0.86, p = 0.02). It is again interesting to note that the incidence of NEC in mARVE neonates (7%) is very similar to the incidence of NEC in HIVU neonates (6%). The mortality among the 13 mARVE neonates who developed NEC however, was 12-times greater than mARVU neonates with NEC (OR 12, CI 1.9 – 76, p = 0.008). Secondary analysis of potential confounders (Table 3.2.5) revealed no difference in gender, gestational age, SGA, or antenatal steroids. There was a trend to better antenatal care among the mARVE neonates that may influence the decreased incidence in NEC but would not explain the higher mortality. The mARVE neonates had a significantly smaller birth weight (median 850g) compared to mARVU neonates (1090g, p = 0.024). In summary, mARVE neonates were less likely to get NEC. Those who did were smaller (all had birth weights under 1000grams), and were more likely to die. It is unclear if this difference in mortality reflects the birth weights of these neonates or the maternal ARV’s.   
HIV-PCR POSITIVE AND NEGATIVE NEONATES  The data for the 11 HIV-PCR positive babies in our study has been included and evaluated comparatively to the known HIV-PCR negative patients. The small numbers as well as factors mentioned in the limitations section below, limit the validity of these observations.  The transmission rate of 4.8% (11/230) is above the reported national average of between 2.1 and 1.6% last reported between 2013 and 2014 [41]. This may reflect an increased risk of vertical transmission in both the premature and LBW infants that has previously been proposed[42].   Unlike the maternal component of PMTCT, Option A and B (Table 2.1) both offer Nevirapine prophylaxis for all HIV-exposed infants. An extended period of cover is incorporated into Option B however if the mothers had inadequate antenatal exposure to ARV’s. Option B additionally suggests HIV-PCR testing earlier than 6 weeks of age based on clinician discretion for a high-risk neonate. The majority of the neonates (177/230, 77%) had HIV-PCR testing done at 6 weeks of age, however all the babies identified as HIV-PCR positive were diagnosed on a HIV-PCR test done before 6 weeks. We have not captured in our data the reasons for the earlier testing, but it would have been either because the infant was unwell with sepsis, NEC, features suggestive of a congenital infection, or because they were identified as having a high transmission risk due to antenatal risk factors. Of our HIVE neonates 86/316 (27%) had no HIV-PCR 
 60 
testing documented. This was either because of the babies dying prior to reaching the 6-week testing point (52/86, 60%) or being discharged prior to 6 weeks of age. While it was possible to trace a HIV-PCR test for many of these infants with a combination of their surname, date of birth or hospital folder number, if the infants were subsequently registered under a different name, relocated provinces or died we had no means of tracing them. As of 2015, South Africa has adopted birth HIV-PCR as a routine practice in PMTCT regimens and identifying these infants should become easier.  The only difference in maternal characteristics among mothers of HIV-PCR positive babies was 90% less exposure to maternal ARV’s (OR 0.12, CI 0.02 – 0.58, p = 0.008). This is not unexpected as an unsuppressed maternal viral load at delivery is a known risk factor for antenatal as well as perinatal transmission [42]. Birth characteristics were similar. Gestational age medians were both 30 weeks for HIV-PCR positive and HIV-PCR negative infants. Birth weights were similar respectively  as well as length-of-stay.  There was no difference in proportion of SGA infants, mortality, early onset  or late onset sepsis  and IVH .  While there was no difference in invasive ventilation and surfactant administration, HIV-PCR positive infants needed 72% less non-invasive ventilation (OR 0.28, CI 0.08 – 0.98, p = 0.046). HIV-PCR positive infants however developed 5-times more chronic lung disease (OR 5.49, CI 1.31 – 23.02, p = 0.02) i.e. still oxygen dependant at 36 weeks post-menstrual age. No further analysis was conducted on the chronic lung disease (CLD) neonates, as the numbers represented are small with only 3/11 HIV-PCR positive babies developing CLD. A sub-group analysis however of the 6 HIV-PCR positive neonates, who received NIV compared to the 177 HIV-PCR negative neonates, did not yield any potential answers (Table 3.3.3). Birth weight and gestational age were similar. There was also no difference in SGA, receipt of antenatal steroids  or surfactant. Factors that HIV-exposure introduces in the development of foetal lungs have previously been mentioned, including a pro-inflammatory in utero environment, which may accelerate lung maturity and explain the decreased need for respiratory support. Additionally, exposure to maternal co-infections and a more vulnerable immune system than HIV-PCR negative neonates may explain the increased incidence of CLD in the HIV-PCR positive neonates.  A 4-fold increased risk of NEC among HIV-PCR positive neonates compared to HIV-PCR negative neonates (OR 4.12, CI 1.02 – 17.18, p = 0.047) was demonstrated. There was no difference in surgery and mortality among these neonates however. The small numbers (3/11 HIV-PCR positive neonates) make further analysis difficult and raise questions around the validity of the result due to inadequate power.  
 
LIMITATIONS 
 A major limitation of the study is that not all neonates received HIV-PCR testing. The deficit in HIV-PCR testing was mostly as a result of PMTCT guidelines during the study, which allowed early testing only for those babies deemed at high risk for infection due to antenatal factors. Of the 53 neonates who received early testing, 11 were HIV-PCR 
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positive while none of the neonates who were considered lower risk and tested later became HIV-PCR positive. This finding is repeated in later studies that were performed [43]. HIV-PCR positive neonates represent a distinct group with an independent risk profile and including them in the analysis may skew the results. It could be argued that an analysis of HIV exposed but uninfected (HIVEU) neonates would be superior. It was not possible to do this however for the following reasons: i.  We could not disregard the HIV-PCR positives, as it is possible that there were other neonates who were HIV infected in the ‘HIV-PCR untested’ group. It is likely however, that the incidence of HIV-PCR positive neonates would be low in this group, as most high-risk transmissions would have been identified and tested early.  ii. We could not disregard the ‘HIV-PCR unknown’ group as a far higher proportion of the HIV-PCR -untested neonates died (53/86; 60%) compared to the HIV-PCR tested group (21/230; 9%). The high mortality rate in the untested group represents a significant proportion of mortality and morbidity data. A consequence of removing the HIV-PCR unknown group would be that HIVE neonates would have a statistically higher chance of surviving than the HIVU neonates. Morbidity outcomes would also be affected in a similar way. It is clear from the above that we had to include both the HIV-PCR positive and the HIV-PCR unknown group in our analysis. Including the HIV-PCR positive group is unlikely to change any findings however due to both the small numbers and the statistical similarities to the HIV-PCR negative neonates. Overall, the data is limited by its retrospective nature. There is also a lack of maternal variables including CD4 counts, cigarette, alcohol and recreational drug use information, socioeconomic factors and nutritional assessments. These factors have important implications for maternal overall health which impacts on neonatal outcomes.  STRENGTHS Overall, this study provides evidence from a large cohort of VLBW neonates with reasonably powered data regarding outcomes of HIVE versus HIVU neonates. Being the first of it’s kind it provides a good foundation from which to focus further research on the topic in similar units in Sub-Saharan Africa.  
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5. CONCLUSION  This is one of the first studies to report on several short-term neonatal outcomes in HIVE, maternal ARV-exposed and HIV-PCR positive VLBW neonates.  For the most part, we did not demonstrate worse short-term neonatal outcomes between HIVE VLBW babies compared to their HIVU counterparts. Similarities included anthropometry and gestation, length-of-stay, sepsis, intraventricular haemorrhage and mortality. The HIVE neonates did demonstrate more need for respiratory support, which does not appear to be related to prematurity. In addition, there was an increased incidence of NEC, which was associated with a lower birth weight.  Adequate maternal ART is associated with improved neonatal outcomes in the areas of respiratory support, NEC and possibly late onset sepsis. In these areas, the neonates behaved similarly to those who were HIV unexposed. The higher mortality rate from NEC in neonates whose mothers received adequate antenatal ART was associated with a birth weight of under 1000grams.  There was a higher HIV-transmission rate compared to the national average that could be expected in our premature, VLBW cohort and was associated with inadequate maternal ART. The data analysis reported based on HIV-PCR -status of the neonates is limited by small numbers and so it is difficult to draw any relevant conclusions.   
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6. RECOMMENDATIONS  1. Further evaluation of HIVE, premature and VLBW neonates in other settings is needed to validate our findings and early HIV-PCR testing is encouraged. 2. Key outcome areas that need further study include respiratory morbidity and NEC.  3. Further study on the increased incidence of NEC should include inpatient breastfeeding/nutrition data to inform the correlation with necrotizing enterocolitis and possibly evaluate for evidence of effect modification. 4. There is a need for evaluation of a larger cohort of HIV-PCR positive infants. Given that the transmission rate is <5%, multi-centre analysis may be the best way to power this research.  5. Maternal ART seems to have some beneficial neonatal outcomes however ongoing surveillance is needed especially considering the possible increased mortality in those who developed NEC.  6. Neonatal care needs to incorporate more promotion of breastfeeding through counselling, breastfeeding support and optimizing maternal health with antiretrovirals.   
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B: Definitions of Data Collection Points  Maternal demographics  
• Ethnicity:  
Restricted to African, White, Asian or Other, which in this population 
predominantly reflected the Cape Malay community, colloquially referred 
to as Coloured. 
• Antenatal care (ANC):  
Defined as any antenatal care and not restricted in terms of number of 
visits or time prior to admission. 
• Chorioamnionitis 
Not limited in terms of specific clinical criteria. Coded if documented as 
such in the maternal or neonatal folder. 
• Antenatal steroids:  
Intramuscular or intravenous administration of betamethasone, 
dexamethasone or hydrocortisone given at any time prior to delivery to the 
mother and not restricted to exclude partial treatment doses. 
• Maternal hypertension:  
Chronic and pregnancy-induced hypertension. PET and eclampsia were 
included in the pregnancy-induced hypertension definition. 
• Type of delivery 
Vaginal delivery vs. Caesarean section.  Neonatal outcomes:  
• Gestational age 
Due to limited access to ultrasound facilities in our referral system these 
were largely determined based on clinical Ballard scores at the time of 
delivery (± 70%) and the remainder based on ultrasound gestation 
determined prior to 20 weeks.[44] 
• Length of stay – duration up until discharge home or death, including if transferred out to other facilities. 
• Delivery room resuscitation: 
o Face-mask ventilation 
o Chest compressions  
o Intubation  
o Adrenaline  administration – given via either the endotracheal or intravenous route 
• Respiratory support at any time during admission 
o Invasive ventilation:  
 High Frequency Oscillation  
 Intermittent Positive Pressure Ventilation) 
o Non-invasive ventilation:  
 CPAP   
  High-Flow Oxygen therapy) 
o Nasal cannulae oxygen 
o Surfactant administration 
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o Chronic lung disease:  
Any infant still requiring supplemental oxygen at 36 weeks post 
menstrual age. 
• Sepsis (based on culture of significant organisms as dictated by prescribed pathogen lists from the Vermont Oxford Network) 
o Early sepsis:  
A positive blood or CSF culture on day 1, 2 or 3 of life. 
o Late sepsis:  
Any positive blood or CSF culture after day 3 of life including 
bacteria and fungi. 
o Nosocomial sepsis:  
Any positive blood or CSF bacterial culture after day 3 of life. 
o Fungal sepsis:  
Any positive blood or CSF fungal culture after day 3.  
o NEC:  Infants needed at least 1 of the prescribed clinical criteria and 1 radiological feature to meet the definition of NEC.  CLINICAL 
 Bilious vomits or gastric aspirates,  
 Abdominal distension   
 Blood in the stools, either occult or visible  RADIOLOGICAL 
 Pneumatosis Intestinalis 
 Hepatobiliary gas 
 Pneumoperitoneum  
• Surgery Major surgery defined by a prescribed list of procedures including NEC, ROP and PDA ligation. Coded in the database as  
 Any surgery 
 NEC  
 ROP 
 Cardiac 
 Neurosurgical 
 Other  
• Intraventricular haemorrhage and cystic periventricular leukomalacia Documented as the worst grade IVH seen on cranial ultrasound in the first 28 days of life and graded as follows –  
 Grade 1: Subependymal germinal matrix haemorrhage only 
 Grade 2: Intraventricular blood, no ventricular dilation 
 Grade 3: Intraventricular blood, ventricular dilation 
 Grade 4: Intraparenchymal haemorrhage 
 Cystic periventricular leukomalacia with multiple small periventricular cysts, excluding echogenicity without cysts or a porencephalic cyst in the area of previously identified Intraparenchymal haemorrhage.  
• Feeding at discharge 
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Documented based on enteral feeding in the 24 hours prior to discharge classified as follows 
 EBM (Exclusive Breast Milk): receiving only human milk either breast-fed or expressed breast milk.  
 Formula: receiving only formula milk. 
 Mixed: receiving human milk, plus human milk fortifier and/or formula milk.    
